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 ABSTRACT 
Recently, we have demonstrated that N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652) (1), adopts a bitopic pose at one protomer 
of a dopamine D2 receptor (D2R) dimer, to negatively modulate the binding of dopamine at the other 
protomer. The 1H-indole-2-carboxamide moiety of 1 extends into a secondary pocket between the 
extracellular ends of TM2 and TM7 within the D2R protomer. To target this putative allosteric site, we 
generated and characterized fragments that include and extend from the 1H-indole-2-carboxamide 
moiety of 1. N-Isopropyl-1H-indole-2-carboxamide (3) displayed allosteric pharmacology and 
sensitivity to mutations of the same residues at the top of TM2 as was observed for 1. Using 3 as an 
‘allosteric lead’, we designed and synthesised an extensive fragment library to generate novel SAR and 
identify N-butyl-1H-indole-2-carboxamide (11d), which displayed both increased negative 
cooperativity and affinity for the D2R. These data illustrate that fragmentation of extended compounds 
can expose fragments with purely allosteric pharmacology.   
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 INTRODUCTION 
G protein-coupled receptors (GPCRs) are the largest superfamily of cell surface receptors and are 
targeted by approximately one third of current medicines.1 There has been an increasing interest in 
targeting allosteric sites within these proteins (sites that are topographically distinct from the 
orthosteric binding site of the endogenous hormone or neurotransmitter) to achieve greater selectivity 
across receptor subtypes.2 More recently, bitopic ligands, i.e. molecules in which orthosteric and 
allosteric pharmacophores have been linked together, have emerged as a new approach to develop 
selective GPCR ligands.3,4 By concomitantly engaging both orthosteric and allosteric sites, bitopic 
ligands combine the advantages of selectivity that can result from engagement of an allosteric site, with 
the high affinity and well-defined structure-activity relationships associated with targeting an 
orthosteric binding pocket.3,5 Such an approach has been successfully exploited to target GPCRs within 
the muscarinic acetylcholine receptor (mAChR) and adenosine receptor families.6-9 In addition, recent 
studies have demonstrated that ligands that selectively target the M1 and M2 mAChRs may achieve 
their receptor-subtype-selectivity through a hitherto unappreciated bitopic mode of interaction.10,11 One 
approach to explore the binding mode of bitopic ligands is to isolate both orthosteric and allosteric 
fragments from the parent structure.10,11 This approach highlights the possibility that one may discover 
novel allosteric ligands for GPCRs by generating fragments of extended ligands that would be expected 
to solely interact with an allosteric pocket rather than the orthosteric pocket.   
The dopamine D1-D5 receptors mediate the physiological functions of the catecholamine 
neurotransmitter, dopamine.12 Many central nervous system diseases are treated with drugs that bind to 
the D2-like dopamine receptors (i.e. the D2S, D2L, D3 and D4 dopamine receptors). Drug discovery at 
these receptors has focused on targeting the orthosteric site with agonists used for the treatment of the 
motor symptoms of Parkinson’s disease and antagonists or low efficacy partial agonists for the 
treatment of schizophrenia. However, allosteric targeting of these receptors may offer several 
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 advantages, including maintenance of spatiotemporal patterns associated with endogenous 
neurohumoral signalling. However, despite such theoretical advantages this approach has yet to be 
exploited therapeutically in part due to the paucity of both allosteric scaffolds for this receptor and 
knowledge of the location of allosteric sites that can be targeted with small molecules.  
 
Figure 1. Structures of dopamine receptor ligands; 1 - negative allosteric modulator of the D2R; 
Eticlopride – selective D2R/D3R antagonist; R-22 – selective D3R antagonist. 
 
Recently, we demonstrated that N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652, 1, Figure 1) is a negative allosteric 
modulator of the D2R. We presented a novel mechanism of action whereby 1 adopts a bitopic pose at 
one protomer of a D2R dimer to modulate the binding of dopamine at the other protomer.
13 We 
generated fragments of 1 that included the 7-cyano-1,2,3,4-tetrahydroisoquinoline (7-CTHIQ) head-
group of 1 to demonstrate that these fragments exhibited competitive antagonism of dopamine and, 
therefore, that this moiety occupies the orthosteric site of the D2R. The crystal structure of the D3R 
bound to the antagonist: (S)-3-chloro-5-ethyl-N-((1-ethylpyrrolidin-2-yl)methyl)-6-hydroxy-2-
methoxybenzamide (eticlopride, Figure 1) and a number of follow-up studies revealed a secondary 
pocket between transmembrane domains  (TMs) 2 and 7 in the receptor structure that can be exploited 
by extended ligands such as (R)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-
indole-2-carboxamide (R-22, Figure 1) to achieve subtype selectivity.14-16 These studies also revealed 
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 that such ligands extend into a similar secondary pocket in the D2R. Using mutagenesis in combination 
with derivatives of 1 we demonstrated that the indole-2-carboxamide moiety of 1 extends into a 
secondary pocket between the extracellular ends of TM2 and TM7 of the D2R. We hypothesize that this 
secondary pocket may an allosteric site that can targeted by allosteric ligands that do not concomitantly 
engage the orthosteric site unlike the bitopic ligand 1. In this study we design and synthesise a library 
of fragments derived from 1 that include and extend from the indole-2-carboxamide moiety of 1 to 
probe the SAR of this putative allosteric site. N-Isopropyl-1H-indole-2-carboxamide (3), the smallest 
fragment of 1 containing the indole-2-carboxamide moiety, displays allosteric pharmacology with 
micromolar affinity for the D2R. We used mutagenesis to demonstrate that this fragment binds in a 
similar allosteric pocket as the indole-2-carboxamide moiety of 1. We then performed an SAR analysis 
using 3 as our lead compound to identify N-butyl-1H-indole-2-carboxamide (11d), which displayed 
both 10-fold increased negative cooperativity and 7-fold increased affinity for the D2R. As such, we 
report indole-2-carboxamides as a novel scaffold, and attractive starting point for the development of 
negative allosteric modulators of the D2R that target an allosteric pocket within the D2R between TM2 
and TM7. These data further confirm the bitopic mode of interaction of 1 and illustrate that 
fragmentation of extended compounds such as 1 can reveal novel allosteric scaffolds. 
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 RESULTS AND DISCUSSION 
Chemistry.  The synthesis of the smallest fragment of 1, N-isopropyl-1H-indole-2-carboxamide (3) 
was achieved in a good yield, through coupling of commercially available 1H-indole-2-carboxylic acid 
(2) and isopropylamine, employing O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HCTU) as a coupling reagent (Scheme 1). 
 
Scheme 1. Synthesis of fragments of 1
a
 
 
a Reagents and conditions: (a) HCTU, isopropylamine, DMF, 75%; (b) i. EtI, K2CO3, MeCN, rt to 
reflux, ii. 50 °C, iii. reflux, 100%; (c) i. dry toluene, -78 °C, ii. DIBAL-H, -78 °C, iii. MeOH, -78 °C, 
100%; (d) (R2)2NH, NaBH(OAc)3, 1,2-dichloroethane, rt, 50-56%; in the case of 7a, the product was 
converted to the corresponding HCl salt form using 1 M HCl/Et2O (e) TFA/DCM (1:3), rt, 96-99%; (f) 
DIPEA, BOP, DCM, 36-49%; in the case of 9a, the product was converted to the corresponding HCl 
salt form using 1 M HCl (aq). 
 
The larger fragments of 1 (compounds 9a-b) were accessible through a five-step procedure, initially 
starting with 2-((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)acetic acid (4). Carboxylic acid 4 
underwent alkylation with EtI in the presence of K2CO3 under reflux conditions in MeCN, to form the 
corresponding ethyl ester 5 in quantitative yield. The partial reduction of 5 was achieved cleanly in the 
(f)
N
H
O
HN
N
R2
R2
NHR3
N
R2
R2
7a R2 = Me; R3 = Boc; HCl salt
8a R2 = Me; R3 = H; di-TFA salt
(e)
(d)
NHBoc
R1
O
4 R1 = OH
5 R1 = OEt
6 R1 = H
(b)
(c)
O
HN
HO
(a)
O
HN
N
H
32
7b R2 = Pr; R3 = Boc
8b R2 = Pr; R3 = H; di-TFA salt
9a R2 = Me; HCl salt
9b R2 = Pr
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 presence of DIBAL-H, with quenching at -78°C, to afford aldehyde 6 in quantitative yield. Reductive 
amination of 6 with either dimethylamine or dipropylamine using NaBH(OAc)3 in 1,2-dichloroethane, 
gave tertiary amine derivatives 7a and 7b, respectively. Compounds 7a-b underwent N-Boc 
deprotection in the presence of TFA/DCM (1:3), to afford diamines 8a-b in the bis-trifluoroacetate salt 
form. Finally, coupling of 8a-b with 1H-indole-2-carboxylic acid (1), employing BOP as the coupling 
reagent, furnished the desired fragment compounds 9a-b (Scheme 1). In the case of 9a, formation of 
the HCl salt in 1 M HCl(aq) was carried out prior to pharmacological evaluation. 
 
Scheme 2. Synthesis of N-substituted-1H-indole-2-carboxamides
a
 
  
a Reagents and conditions: (a) MeOH, concentrated H2SO4, reflux, 98%; (b) amine/amine solution, 
EtOH, rt, 34-76%; (c) HCTU, DMF, excess amine or stoichiometric amine and DIPEA, rt, 34-81%. 
 
Our initial library of compounds focused on analogues of 3 varied at the carboxamide moiety. 
Synthesis of target amides 11a-w was achieved by either HCTU-mediated coupling (11g-h, j-w), with 
a series of commercially available amines (in a similar fashion to the synthesis of 3), or by direct 
aminolysis of the intermediate methyl ester 10 (Scheme 2). Methyl ester 10 was obtained from 
carboxylic acid 2 in near-quantitative yield, through esterification by reflux in MeOH, in the presence 
of catalytic concentrated H2SO4. Subsequent direct aminolysis of 10 carried out in EtOH at rt, in the 
(c)
10
N
H
O
O
(a)
N
H
O
OH
N
H
O
R4
2
11a-w
(b)
R4 = k azetidin-1-yl
l pyrrolidin-1-yl
m piperidin-1-yl
n morpholin-4-yl
o cyclopropylamino
p cyclobutylamino
q cyclopentylamino
r cyclohexylamino
s (piperidin-1-yl)amino
t phenylamino
u (cyclopropylmethyl)amino
v (cyclohexylmethyl)amino
w benzylamino
a NH2
b NHEt
c NHnPr
d NHnBu
e NHCH2CH=CH2
f NHCH2CH2OH
g NHCH(Et)2
h NHtBu
i N(Me)2
j N(iPr)2
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 presence of excess amine or amine solution, afforded 11a-f and 11i in modest to good yield. This 
extensive library of 1H-indole-2-carboxamides was comprised of compounds designed to interrogate 
the effect of introducing increasing size of both linear and branched alkyl chains, saturated and 
aromatic carbocycles and also amides with varying levels of N-substitution. 
The systematic introduction of the electronegative element fluorine into various positions on 
aromatic ring scaffold, known as a “fluorine walk”, has in the past uncovered derivatives of the parent 
compound with improved potency or physicochemical characteristics; in particular this strategy was 
employed in SAR studies of the prototypical positive allosteric modulator of the M1 mAChR – 
BQCA.17,18 As a second area of investigation, we sought to generate a small library of mono-fluoro-
substituted N-isopropyl-1H-indole-2-carboxamides (13a-e), in addition we synthesized the 
corresponding 5-methoxy analogue of 3 (Scheme 3). 
 
Scheme 3. Synthesis of substituted N-isopropyl-1H-indole-2-carboxamide
a 
 
 
a Reagents and conditions: (a) i. Sat. NaHCO3 (aq), MeCN, 0 °C, ii. 1-Chloromethyl-4-fluoro-1,4-
diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate), rt, 46%; (b) HCTU, isopropylamine, DMF, rt, 7-
80%. 
(b)
12b
N
H
O
OH
R5
R = 4-F
N
H
O
HN
R5
(a)
13a
N
H
O
HN
3
N
H
O
HN
F
12c R = 5-F
12d R = 6-F
12e R = 7-F
14 R = 5-OMe
13b R = 4-F
13c R = 5-F
13d R = 6-F
13e R = 7-F
15 R = 5-OMe
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3-Fluoro-N-isopropyl-1H-indole-2-carboxamide (13a) was accessed in moderate yield, through 
fluorination of 3 using the electrophilic fluorine source 1-chloromethyl-4-fluoro-1,4-
diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate), adapting literature methodology.19 The remaining 
fluoro- and methoxy-substituted analogues (13b-e, 15) were obtained through HCTU-mediated 
coupling the corresponding commercially available carboxylic acid precursors (12b-e, 14) with 
isopropylamine as described above. 
 
Scheme 4. Synthesis of N-isopropyl carboxamide-substituted heterocycles
a 
 
a Reagents and conditions: (a) HCTU, isopropylamine, DMF, rt, 22-90%; (b) LiOH.H2O, THF/water 
(1:1), rt, 78-100%; 
 
Z
(a)
17
Y
X O
OH Z Y
X O
HN
X = Z = CH; Y = NMe
19 X = N; Y = NH;  Z = CH
21 X = N; Y = O; Z = CH
23a X = Z = CH; Y = O
25a X = Z = CH; Y = S
(a)
23b
Y Y
Y = O
25b Y = S
OH
O
NH
O
(b)
N
H
O
O
(a)
27 X = CH; Y = NH; Z = N
16 X = Z = CH; Y = NMe
18 X = N; Y = NH;  Z = CH
20 X = N; Y = O; Z = CH
22a X = Z = CH; Y = O
24a X = Z = CH; Y = S
26 X = CH; Y = NH; Z = N
22b Y = O
24b Y = S
N
H
O
HO N
H
O
NH
28a-d 29a-d 30a-d
Substituent position: a = 4; b = 5; c = 6; d = 7
Page 9 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Our final series of fragment analogues used a series of aromatic core replacements to ascertain 
whether the allosteric modulatory activity of 3 could be affected by the electronic nature of the bicyclic 
heteroaromatic ring, or the presence of the hydrogen-bond donor moiety of the indole (Scheme 4). In 
addition, we also wanted to investigate positional isomers of 3, where the attachment point of the N-
isopropylcarboxamide was varied around the indole scaffold (Scheme 4). 
The N-methyl-1H-indole, benzo[d]imidazole, benzo[d]oxazole, benzofuran, benzo[b]thiophene and 
pyrrolo[2,3-b]pyridine analogues of 3 (compounds 17, 19, 21, 23a, 25a and 27, respectively) were once 
again easily synthesized through HCTU-mediated coupling of the parent carboxylic acid with 
isopropylamine. Considered to be of interest also, were the 3-substituted benzofuran, 
benzo[b]thiophene analogues (23b and 25b) which were obtained in the same manner. 
Finally, synthesis of the series of positional isomers of 3 was carried out in a two-step procedure. 
Attempted direct aminolysis of commercially available methyl esters 28a-d proved unsuccessful, 
therefore, initial basic hydrolysis of the esters to give the corresponding carboxylic acids 29a-d was 
carried out. Final HCTU-mediated coupling of 29a-d with isopropylamine gave the desired 
carboxamides 30a-d (Scheme 4). 
Pharmacological analysis of the series of carboxamide fragments revealed the N-butyl-1H-indole-2-
carboxamide 11d, to have higher affinity for the D2R and greater negative cooperativity with dopamine 
as compared to the parent fragment 3 (see below). With this in mind, we sought to synthesise an 
analogue of 1 incorporating the structure of 11d (Scheme 5), anticipating that combining the 7-CTHIQ 
and 11d moieties would proffer a higher affinity D2R bitopic ligand. The target compound 36 was 
prepared as described previously (Scheme 5).20 
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 Scheme 5. Synthesis of a prospective higher affinity bitopic ligand incorporating fragment 11d
a 
 
a Reagents and conditions: (a) Boc2O, TEA, DCM, rt, 82%; (b) MsCl, TEA, DCM, rt, 93%; (c) 7-
CTHIQ, DIPEA, DCM, reflux, 12%; (d) i. TFA/DCM (1:5), rt; ii. neutralization; (e) 2, HCTU, DIPEA, 
DMF, rt, 69%. 
 
Pharmacology. 
Fragments of 1 containing the indole-2-carboxamide moiety display allosteric pharmacology. In 
previous work we demonstrated that 1 binds as a bitopic ligand to one protomer of a homodimer of the 
D2R to modulate the binding of a ligand to the orthosteric site of a second protomer.
13 We previously 
identified purely orthosteric fragments of 1 containing the 7-CTHIQ moiety that displayed competitive 
pharmacology with dopamine. This core group comprises the key elements expected to interact with 
the orthosteric binding site of aminergic receptors (i.e. an aromatic ring in close proximity to a charged 
nitrogen at physiological pH). In the current study we have derived fragments extending from the 
indole-2-carboxamide moiety of 1 (distal to the 7-CTHIQ orthosteric head-group), with the aim to 
provide further validation of the bitopic mode of action of 1. In addition we wanted to examine whether 
the approach of dividing bitopic ligands into discrete fragments can unmask novel purely allosteric 
scaffolds.  
N
H
O
HN
N
NC
R6
R7
31 R6 = OH; R7 = NH2
32 R6 = OH; R7 = NHBoc
33 R6 = OMs; R7 = NHBoc
(a)
(b)
(c)
R7
N
NC
34 R7 = NHBoc
35 R7 = NH2
(d)
(e)
36
Page 11 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
Figure 2 a) 
b) pERK1/2 cAMP c) 
d) 
[
35
S] GTPγS 
-9 -8 -7 -6 -5 -4 -3 -2
0
20
40
60
80
100
120
Log[dopamine] (M) 
%
 m
a
x
im
a
l 
s
tim
u
la
tio
n
 
o
f 
d
o
p
a
m
in
e
 
0 
3 
10 
30 
100
300
[3] (µM)
-8 -7 -6 -5 -4 -3 -2 -1
0
20
40
60
80
100
120
Log[dopamine] (M) 
%
 [
3
H
] 
s
p
ip
e
ro
n
e
 b
in
d
in
g
0
300
100
30
10 
3 
[3] (µM)
-11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
Log[dopamine] (M) 
p
E
R
K
1
/2
(%
F
B
S
)
0
3
10
30
100
300
[3] (µM)
e) 
-8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
Log[ligand] (M) 
%
 [
3
H
] 
s
p
ip
e
ro
n
e
 b
in
d
in
g
1
3
-12 -11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
Log[dopamine] (M)
%
 m
a
x
im
a
l 
s
ti
m
u
la
ti
o
n
 
d
o
p
a
m
in
e
 i
n
 c
o
n
tr
o
l 
c
o
n
d
iti
o
n
0
3
10
30
100
300
[3] (µM)
-12 -11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
Log[dopamine] (M)
%
 m
a
x
im
a
l 
s
ti
m
u
la
ti
o
n
 
d
o
p
a
m
in
e
 in
 c
o
n
tr
o
l 
c
o
n
d
it
io
n
0
3
10
30
100
300
[3] (µM)
f) g) 
Radioligand binding Radioligand binding 
Gα
o1
 activation: D
2
R Gα
o1
 activation: D
3
R 
Page 12 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Figure 2. A fragment of 1 containing the indole-2-carboxamide pharmacophore (3) inhibited the action 
of dopamine D2R in a non-competitive manner, in functional assays measuring: (a) D2R mediated 
[35S]GTPγS binding; (b) inhibition of forskolin stimulated cAMP; (c) ERK1/2 phosphorylation. Data 
were fitted using an allosteric ternary complex model ([35S]GTPγS and cAMP, Equation 4) or an 
operational model of allosterism (pERK1/2, Equation 5), to derive values of affinity and cooperativity 
(Table 1). (d) Both 1 and 3 caused partial displacement of the binding of [3H]spiperone in an 
equilibrium binding assay consistent with an allosteric mode of action. (e) Dopamine-mediated 
inhibition of the equilibrium binding of [3H]spiperone in the absence or presence of 3. Data points 
represent the mean ± SEM of three experiments performed in duplicate. Curves drawn through the data 
points represent the best fit of a two-site allosteric ternary complex model (Equation 1, Table 1). 
Compound 3 interacts with the D2R (f) and the D3R (g) in an allosteric manner in an assay measuring 
GaoB G protein activation. 
 
 
Table 1. Characterization of fragments of 1 containing the indole-2-carboxamide moiety in terms 
of binding and function at the D2R
a 
 
[35S]GTPγS cAMP pERK1/2 [3H]spiperone binding 
pKB  
(KB, µM) 
Logαβ  
(αβ)  
pKB  
(KB, µM) 
Logαβ  
(αβ) 
pKB  
(KB, µM) 
Logα 
(α) 
Logβ 
pKB  
(KB, µM) 
Logα  
(α) 
Logα′ 
(α′) 
3 
4.89 ± 0.29 
(13) 
-0.89 ± 0.17 
(0.13) 
4.72 ± 0.29 
(19) 
-0.54 ± 0.09 
(0.28) 
4.35 ± 0.06 
(45) 
-0.53 ± 0.13 
(0.30) 
-100 
4.88 ± 0.17 
(13) 
-0.51 ± 0.04 
(0.31) 
-0.53 ± 0.04 
(0.30) 
9a 
5.54 ± 0.4 
(3) 
-0.84 ± 0.15 
(0.14) 
ND ND 
5.54 ± 0.4 
(3) 
-0.61 ± 0.14 
(0.25) 
-100 - - - 
aThe ability of 3 or 9a to modulate the functional effect of agonists or their affinity for the D2R 
expressed in Flp-IN CHO cells was tested at various signaling endpoints. For [35S]GTPγS and cAMP 
assays data was fitted to an allosteric ternary complex model (Equation 4) whereas for pERK1/2 
assays data was fit to an operational model of allosterism (Equation 5) to derive values of affinity 
(pKB) and cooperativity. Radioligand binding data were fitted with Equation 1 to derive values of 
cooperativity with dopamine (Logα) and [3H]spiperone binding (Logα′) 
 
Our previous study demonstrated that the indole-2-carboxamide moiety of 1 extended into a 
secondary ‘allosteric’ pocket within the D2R.
13 Accordingly, we first synthesised the fragment 3, 
(Scheme 1, Figure 2a) with the hypothesis that this fragment would act as a modulator of dopamine 
binding and/or function. Our characterization of 3 revealed this small molecule inhibited the action of 
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 dopamine in a manner that was best fit by an allosteric model in both functional and ligand binding 
assays. When an interaction study with dopamine was performed in either a [35S]GTPγS assay (Figure 
2a) or an assay measuring D2R-mediated inhibition of forskolin-stimulated cAMP production (Figure 
2b), 3 caused a limited 8-fold or 3-fold reduction in agonist potency, respectively (Figure 2b). 
Application of an allosteric ternary complex model to the concentration response data yielded estimates 
of affinity for the unoccupied receptor ([35S]GTPγS assay, KB = 13 µM: cAMP assay, KB = 19 µM) and 
its cooperativity with dopamine ([35S]GTPγS assay, αβ = 0.13: cAMP assay, αβ = 0.29; where α 
represents cooperativity with dopamine affinity, β represents modulatory effect upon dopamine 
efficacy and values less than 1 indicate negative cooperativity, Table 1). This pattern was distinct from 
that observed in an assay measuring ERK1/2 phosphorylation, in which 3 caused both a reduction in 
dopamine potency and a significant decrease in maximal response (Figure 2c). This latter observation 
is consistent with negative modulation of orthosteric ligand efficacy.21 Accordingly, data were fitted 
using an operational model of allosterism whereby Logβ was fixed to -100 to reflect the high negative 
modulatory effect of 3 upon dopamine efficacy. This analysis allowed estimation of an affinity value 
(KB = 46 µM) for 3 and its cooperativity with dopamine binding (α = 0.29) (Table 1). However, 
because of the low affinity of 3 and its relatively weak modulatory effect upon dopamine potency we 
sought additional evidence of an allosteric mode of interaction. Therefore, we extended our 
characterization to a radioligand-binding assay. We first tested the ability of 3 to antagonize 
[3H]spiperone and found that increasing concentrations of 3 produced only a partial displacement of 
this radioligand consistent with an allosteric mode of interaction (Figure 2d). We extended these 
studies to perform a binding interaction study to investigate the effect of increasing concentrations of 3 
on the affinity of both dopamine and the radiolabeled antagonist [3H]spiperone. The value of affinity 
derived for 3 (KB = 13 µM) was consistent with that determined in each functional assay (Figure 2e, 
Table 1). In addition, 3 was a negative modulator of both dopamine (α = 0.31) and [3H]spiperone (α = 
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 0.30) affinity. These values indicate that, whilst the magnitude of negative allosteric modulation of 
dopamine affinity is consistent across all assays, the decrease of dopamine Emax in the pERK1/2 assay 
is consistent with additional effects of 3 upon dopamine efficacy. Such a distinct pattern of action may 
indicate that 3 differentially antagonizes the effect of dopamine at different signalling endpoints. 
However, the sensitivity of the respective assays and the different assay conditions of the various 
assays may also underlie this effect although it is interesting to note that the parent compound, 1, 
demonstrated a profile of modulation whereby the degree of negative cooperativity with dopamine 
could be attributed solely to an effect on dopamine affinity and was not significantly different across 
these different pathways.14 Compound 1 has been shown to display approximately 50-fold selectivity 
for the D3R over the D2R.
22,23 Furthermore, it was postulated that this subtype selectivity was driven 
through interaction of the indole-2-carboxamide moiety of 1 with an extended pocket.15 The D3R has 
been shown to selectively couple to the Gαo1 G protein whereas the D2R can couple to all members of 
the Gαi/o G protein family.
24 Accordingly, we assessed the action of 3 at the D2R (Figure 2f) compared 
to the D3R (Figure 2g) in an assay measuring activation of Gαo1 G protein using a bioluminescence 
resonance energy transfer (BRET) biosensor.25  This revealed that 3 displays both affinity (D2R pKB = 
4.84 ± 0.27 (KB = 14 µM): D3R, pKB = 5.05 ± 0.21 (KB = 9 µM)) and negative cooperativity (D2R, logα 
= -0.77 ± 0.14 (α = 0.17): D3R, logα = -1.13 ± 0.16 (α = 0.07) that is not significantly different between 
the D2R and D3R. 
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Figure 3. A fragment of 1 containing the indole-2-carboxamide pharmacophore and extending to a 
tertiary amine (emulating the position of that present on the 7-CTHIQ moiety) interacts with the D2R in 
a mixed orthosteric/allosteric manner, in functional assays measuring: (a) D2R mediated [
35S]GTPγS 
binding, and (b) ERK1/2 phosphorylation, 9a inhibited the action of dopamine in a non-competitive 
manner.  Data were fitted using an allosteric ternary complex model ([35S]GTPγS, Equation 4) or an 
operational model of allosterism (pERK1/2, Equation 5) (Table 1). (c) Dopamine-mediated inhibition 
of the equilibrium binding of [3H]spiperone in the absence or presence of 9a. Data points represent the 
mean ± SEM of three experiments performed in duplicate. Curves drawn through the data points 
represent the best fit of a two-site binding model.26 
 
One would also expect that extension of the purely allosteric pharmacophore to include structural 
features of the orthosteric moiety, incorporating a suitable linker moiety in between, would result in the 
generation of ligands that displayed competitive behaviour with an orthosteric ligand. We generated 
additional fragments of 1 that extended away from the indole-2-carboxamide moiety and included a 
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 tertiary amine group (emulating that present on the 7-CTHIQ moiety of 1). Characterisation of 9a 
(Figure 3, Scheme 1) was consistent with either an allosteric mode of interaction ([35S]GTPγS (Figure 
3a) and pERK1/2 (Figure 3b) or competitive mode of interaction (radioligand binding) (Figure 3c, 
Table 1). This discrepancy is most likely due to the larger molecular size of spiperone as compared to 
dopamine whereby 9a may be able to occupy the D2R simultaneously with dopamine but not with 
spiperone. Of interest, the allosteric mode of interaction suggests that the protonated amino group of 9a 
does not project into the area occupied the protonated amino of dopamine. If one considers the 
competitive action of fragments of 1 that contain the 7-CTHIQ moiety, this suggests that the orientation 
of the amino group of 9a and the amino group within the 7-CTHIQ moiety of 1 must be different.  
These data also highlight the proximity of the orthosteric and allosteric pockets.  
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Figure 4. A more extensive fragment of 1 containing the indole-2-carboxamide pharmacophore and 
extending to a tertiary amine (emulating the position of that present on the 7-CTHIQ moiety, but with 
longer alkyl chains compared to 9a) is a partial agonist at the D2R. To investigate the mode of 
interaction of 1 with the D2R we synthesised compound 9b.  In functional assays measuring: (a) D2R-
mediated inhibition of forskolin stimulated cAMP production, and (b) ERK1/2 phosphorylation, 9b 
behaved as a partial agonist.  In the pERK1/2 assay, 9b inhibited the action of dopamine in a non-
competitive manner decreasing Emax but also displayed agonism in its own right. In contrast in the 
cAMP assay, 9b behaved as a competitive partial agonist. (c) Dopamine-mediated inhibition of the 
equilibrium binding of [3H]spiperone in the absence or presence of 9b. Data points represent the mean 
± SEM of three experiments performed in duplicate. Curves drawn through the data points represent 
the best fit of a two-site binding model26 (Supplementary Table 1). (d) The ability of 1 and fragments 
of 1 to displace [3H]spiperone  at the D2R.  Both 1 (pKB = 6.29 ± 0.07, Logα = -0.46 ± 0.02) and 3 (pKB 
Compound 3 = 4.75 ± 0.23, LogαCompound 3 = -0.23 ± 0.03) demonstrate an inability to completely displace 
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 [3H]spiperone in agreement with an allosteric mode of interaction (Equation 2). In contrast, data of 
both 9a and 9b, which possess a tertiary amine group (positioned atomically the same distance as that 
present on the 7-CTHIQ of 1), were best fitted by a one-site competitive model,26 with estimated 
affinity of pKI_Compound 9b = 4.70 ± 0.03. 
 
Extension of the fragment further to generate 9b (Figure 4, Scheme 1) yielded a low affinity partial 
agonist with a strictly competitive mode of interaction with dopamine in all assays, with the exception 
of the pERK1/2 assay, in which a concentration-dependent decrease in maximal agonist effect was 
observed (Figure 4). This suggests that the extended alkyl chains of 9b either reorientate this ligand 
relative to the position of 9a so that the protonated amino moiety now occupies and competes directly 
with the amino moiety of dopamine. Alternatively, if the orientation of 9b is equivalent to that of 9a 
whereby the protonated amine does not compete with that of dopamine the additional length of the 
alkyl chain substitutions may extend into the binding pocket of dopamine. In either case agonism 
appears to be concomitant with competition with dopamine. 
 
Compound 3 is modulated by the mutation of residues within a secondary binding pocket of the 
D2R. While the ability to separate orthosteric and allosteric fragments from 1 is consistent with its 
bitopic mode of interaction at the D2R, it does not necessarily follow that the allosteric fragment 3 will 
occupy the same binding pocket as that of the corresponding indole-2-carboxamide moiety of 1.  
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Figure 5. Mutation of residues at the top of TM2 modulates the allosteric action of 3; (a) When docked 
into a homology model of the D2R the 7-CTHIQ core of 1 occupies the orthosteric pocket. The 1H-
indole-2-carboxamide moiety of 1 extends into a secondary pocket between TM2 and TM7, where the 
indolic NH makes a hydrogen bond interaction with Glu952.65,
 and the 1,4-cyclohexylene group makes 
a hydrophobic interaction with Val912.61 (Figure recreated from modeling studies previously 
published14). Mutation of these residues decreases the affinity or negative cooperativity of 1. 
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 Interaction studies between 3 and dopamine in an assay measuring D2R mediated pERK1/2 
phosphorylation using CHO cells expressing the (b) WT, (c) Val912.61Ala or (d) Glu952.65Ala. 
 
 
Table 2: Characterization of binding and function of N-isopropyl-1H-indole-2-carboxamide (3) at 
the D2R
a  
 1 3 
 
pKB 
c 
(KB, µM) 
Logαβ 
c 
(αβ) 
pKB  
(KB, µM) 
Logα  
(α) 
Logβ  
(β) 
Wild Type 6.26 ± 0.09 
(0.55) 
-1.22 ± 0.11 
(0.06) 
4.35 ± 0.06 
(45) 
-0.53 ± 0.13 
(0.29) 
-100 
Val91
2.61
Ala 6.26 ± 0.09 
(0.55) 
-0.48 ± 0.16 
(0.33) 
-b - - 
Glu95
2.65
Ala 5.31 ± 0.19 
(4.90) 
-0.32 ± 0.14 
(0.48) 
6.38 ± 0.31 
(0.04) 
0.12 ± 0.12 
(1.31) 
-0.81 ± 0.11 
(0.15) 
      
aThe ability of 3 to modulate the functional effect of agonists or their effect at either the WT D2R or 
mutant D2Rs expressed in Flp-IN CHO cells was tested in a pERK1/2 assay and data was fit to an 
operational model of allosterism (Equation 5) to derive values of affinity (pKB) and cooperativity with 
dopamine. b no effect of 3 was observed up to concentration of 300 µM. cValues taken from14. 
 
Our previous study identified two residues at the top of TM2 (Val912.61 and Glu952.65) that interact 
with the indole-2-carboxamide moiety of 1 and mutation of these residues to alanine reduced the 
affinity and/or negative cooperativity of 1 (Figure 5a, Table 2).13 We hypothesised that if 3 occupies 
the same binding pocket as the 1H-indole-2-carboxamide moiety of 1, then one would expect a similar 
sensitivity to mutation of these residues. Mutation of Val912.61Ala removed any effect of 3 up to a 
concentration of 300 µM upon a dopamine in a pERK1/2 assay, indicating this residue is key for 3 
binding or function (Figure 5b, Table 2). This mutation caused no change in affinity of 1 but caused a 
5-fold decrease in negative cooperativity with dopamine. This indicates that 1 makes additional 
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 interactions, most likely within the orthosteric pocket of the D2R, which are the main contibutors to 
affinity. In contrast, the mutation of Glu952.65Ala caused a 100-fold increase in affinity and a complete 
abolition of negative cooperativity with dopamine affinity (Figure 5d, Table 2). In addition, while 3 at 
the WT D2R (Figure 2c) displayed high negative modulation of dopamine efficacy (Logβ = -100) this 
modulatory effect was more limited at the Glu952.65Ala (β = 0.15) (Figure 5b & d, Table 2). This is 
quite different to the effect of this mutation upon 1, where both an 8-fold decrease in negative 
cooperativity and a 9-fold decrease in affinity was observed.  It is important to note that these 
mutations caused no change in the affinity of dopamine. Therefore, these results suggest that 3 
occupies a similar binding site between TM2 and TM7 of the D2R to the 1H-indole-2-carboxamide 
moiety of 1 although it is important to note the individual contribution of the different residues to 
binding affinity and cooperativity differ between 1 and 3. Therefore, we must acknowledge the 
possibility that the orientation of 3 within this pocket may be different to that of 1H-indole-2-
carboxamide moiety of 1. Furthermore, because we cannot measure binding of 3 directly (i.e with a 
radiolabelled derivative) then we must also consider the possibility that the effects of such mutations, 
rather than indicating a direct residue-ligand interaction, may result from an allosteric effect i.e. 
mediated by a global change in receptor conformation. 
We then conducted a detailed SAR study to understand the structural determinants of the allosteric 
action of 3 and to generate derivatives with higher affinity and/or negative cooperativity. 
 
Preliminary investigation into the SAR of indole and related heterocycle carboxamide derivatives 
The most complex allosteric behaviour for compound 3 was observed in the pERK1/2 phosphorylation 
assay in which increasing concentrations of the modulator caused both a decrease in dopamine affinity 
and maximal effect. Moreover, this assay provides a robust, medium-throughput measurement of D2R 
activation. As such, all derivatives of compound 3 were screened using this assay. We observed four 
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 distinct patterns of ligand action across the entire series of compounds (Table 3 & 4). A number of 
compounds caused both a rightward displacement of the dopamine concentration-response curve and a 
decrease in the maximal response of dopamine that did not reach a limit within the concentration range 
used. These data were analyzed according to an operational model of allosterism (as for compound 3, 
Figure 1) to determine a value of affinity (KB) and binding cooperativity parameter (α) between 
dopamine and the allosteric ligand (where Logβ was constrained to -100 to represent high negative 
modulation of dopamine efficacy). Other compounds caused a limited rightward shift of the dopamine 
dose-response curve but no decrease in Emax. These data were fit using an operational model of 
allosterism where Logβ was constrained to 0 to represent no effect upon dopamine efficacy. A number 
of compounds produced an unlimited rightward shift of a dopamine dose-response curve within the 
concentration range of test compound used. Accordingly, data were fit with a competitive model to 
allow an estimate of affinity for the D2R. However, because the concentration range used to test these 
compounds was restricted by compound solubility we cannot exclude the possibility that these 
compounds also act by binding to an allosteric pocket while maintaining high negative cooperativity 
with dopamine. Finally, some compounds had no effect upon the dopamine dose-response curve within 
the range of compound tested. 
 
 
Table 3. Characterization of analogues of compound 3, varied at the carboxamide N-substituent 
and indole-substitution in terms of binding and function at the D2R
a
 
 
No. R
1
 R
2
 pKB  (KB, µM) Logα (α) 
3
b
 
 
H 4.35 ± 0.07 (45) -0.53 ± 0.09 (0.29) 
11a  H ND ND 
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 11b
b
 
 
H 3.67 ± 0.14 (214) -0.35 ± 0.21 (0.45) 
11c
b
 
 
H 4.21 ± 0.06  (62) -0.60 ± 0.09  (0.25) 
11d
b
 
 
H 5.21 ± 0.07  (6) -1.63 ± 0.11 (0.02) 
11e
b
 
 
H 5.33± 0.21  (5) -0.26  ±0.06  (0.55) 
11f 
 
H ND ND 
11g
d
 
 
H 4.41 ± 0.14  (39) NA 
11h
b
 
 
H 4.30 ± 0.06  (50) -0.58 ± 0.13  (0.26) 
11i 
 
H ND ND 
11j
b
 
 
H 4.72 ± 0.10  (19) -1.39 ± 0.11  (0.04) 
11k 
 
H ND ND 
11l
d
 
 
H 3.08 ± 0.11  (831) NA 
11m 
 
H ND ND 
11n 
 
H ND ND 
11o
d
 
 
H 3.81 ± 0.08  (154) NA 
11p
c
 
 
H 4.77 ± 0.13  (17) -1.77 ± 0.27  (0.02) 
11q
b
 
 
H 4.72 ± 0.26  (19) -0.63 ± 0.11  (0.23)  
11r 
 
H ND ND 
11s
b
 
 
H 4.04 ± 0.10  (91) -0.53 ± 0.13  (0.30) 
11t
d
 
 
H 4.73 ± 0.34  (19) NA 
11u
b
 
 
H 4.53 ± 0.07  (30) -1.01 ± 0.08  (0.10) 
11v 
 
H ND ND 
11w 
 
H ND ND 
13a
b
 
 
3-F 4.35 ± 0.29  (45) -0.72 ± 0.35  (0.19) 
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 13b
b
 
 
4-F 4.74 ± 0.10  (18) -1.14 ± 0.10  (0.07) 
13c
d
 
 
5-F 4.04 ± 0.08  (91) NA 
13d
d
 
 
6-F 4.26 ± 0.17  (55) NA 
13e
b
 
 
7-F 4.74 ± 0.11  (18) -0.96 ± 0.12  (0.11) 
15
d
 
 
5-OMe 3.98 ± 0.20  (104) NA 
 
aInteraction studies between compounds and dopamine were performed using an ERK1/2 
phosphorylation assay upon FlpIn CHO cells stably expressing the D2LR as in Figure 1c.  
bFor 
compounds that caused a decrease in the maximal response of dopamine, data were analysed according 
to an operational model of allosterism where KB is the equilibrium dissociation constant of the 
allosteric ligand, α is the binding cooperativity parameter between the orthosteric and allosteric ligand, 
and β (Logβ constrained to -100 to represent high negative cooperativity with dopamine efficacy) 
denotes the magnitude of the allosteric effect of the modulator on the efficacy of the orthosteric 
agonist. cFor compounds that caused a limited rightward shift of the dopamine dose-response curve but 
no decrease in Emax, data were fit using an operational model of allosterism where Logβ was 
constrained to 0, to represent neutral cooperativity with dopamine efficacy. dFor compounds that 
produced an unlimited rightward shift of a dopamine dose-response curve within the concentration 
range of test compound used data were fit using model of competitive antagonism (Equation 6) .  As 
such a value of cooperativity could not be derived (denoted NA). ND signifies no effect of compound 
was observed even at the highest concentration of 300 µM. Data represent the mean ± SEM of three 
experiments performed in duplicate apart from compounds with no effect, which were tested in two 
separate experiments. 
 
The subtle differences and stepwise structural changes introduced to members of the fragment library 
reveal some interesting SAR in terms of both their binding and function at the D2R (Table 3). 
Considering analogues of 3 varied only at the carboxamide N-substituent, substitution appears to be 
essential for binding to the receptor, as the primary amide derivative 11a does not exhibit receptor 
binding at even the highest concentrations employed. Furthermore, the degree of N-substitution of the 
carboxamide moiety is also a key determinant of affinity (KB), with mono-substituted derivatives (3, 
11b-e, g-h, o-q, t-u) exhibiting activity, whereas the majority of di-substituted derivatives (11i, k, m-n) 
did not. 
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 Comparing the mono-substituted carboxamide analogues of 3 bearing non-cyclic N-substituents 
(11b-h), increasing the size of linear alkyl substituents from N-ethyl (11b KB = 214 µM, α = 0.45), to 
N-propyl (11c KB = 62 µM,α = 0.25), to N-butyl (11d KB = 6 µM, α = 0.02), improved both affinity and 
increased negative cooperativity in a progressive fashion. This demonstrates the importance of N-
substituent chain length to both binding and negative cooperativity. Interestingly, the N-allyl analogue 
11e (KB = 5 µM, α = 0.55) is of comparable size to 11c, but differs only in the degree of saturation in 
the N-substituent. However, this subtle structural difference results in around a 10-fold increase in 
affinity, but approximately 2-fold decrease in negative cooperativity; suggesting that affinity and 
negative cooperativity are driven by different structural features of these allosteric fragments, i.e. 
simply increasing fragment affinity does not automatically result in increased negative cooperativity. 
The inactivity of the ethanolamide analogue 11f indicates that polarity in the carboxamide N-
substituent is not tolerated, suggesting that this region of the molecule may largely interact with 
hydrophobic residues. The two branched amide analogues 11g (KB = 39 µM) and 11h (KB = 50 µM, α = 
0.26) both displayed similar affinity to 3, however N-(pentan-3-yl) analogue 11g lacked determinable 
negative cooperativity. These data, when combined with the activity profile of N-ethyl analogue 11b, 
suggest that an optimal degree of branching may be present on the N-isopropyl substituent of 3 both in 
terms of degree of substitution of the carbon atom adjacent to the carboxamide nitrogen in addition to 
branch length. Further branching to the N-tert-butyl present on 11h does not appear to impact affinity 
or cooperativity. Extending the branch length of the N-isopropyl group of 3 to the N-(pentan-3-yl) 
group of 11g did not affect affinity and the effect on negative cooperativity was indeterminable. In 
comparison, reducing branching (i.e. 3 vs 11b) causes both affinity and negative cooperativity to 
reduce. 
Di-substituted carboxamide derivatives largely comprised of aliphatic heterocycle bearing analogues 
(11k-n). Of these, only pyrrolidyl analogue 11l (KB = 831 µM) displayed some, albeit weak affinity, 
Page 26 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 with no detectable negative cooperativity. Although the di-substituted amide derivatives generally 
lacked affinity, the N-diisopropyl analogue 11j (KB = 19 µM, α = 0.04) possessed both higher affinity 
and almost 10-fold higher negative cooperativity than 3. This activity is difficult to rationalize amidst 
the data for other compounds in the library. However, given the fragment-size nature of these 
compounds, the possibility of alternative binding poses should not be discounted. 
The remaining analogues in this series comprised cyclic moieties with the linking nitrogen atom 
external to the ring. In the N-carbocycle series, ring size influenced both affinity and negative 
cooperativity when comparing N-cyclopropyl 11o (KB = 154 µM), N-cyclobutyl 11p (KB = 17 µM, α = 
-0.02), N-cyclopentyl 11q (KB = 19 µM, α = 0.23) and N-cyclohexyl 11r (no determinable activity) 
analogues. The optimal size in terms of affinity and highest level of negative cooperativity is exhibited 
by the N-cyclobutyl bearing 11p. Incrementing ring size by a single methylene unit to give 11q does 
not affect affinity, but causes approximately 10-fold reduction in negative cooperativity. This data 
supports the SAR discussed above, of the acyclic substituents, with 11o-p being most similar in size 
and shape to 3, whereas 11q-r are more comparable to 11g. The inactivity of 11r may initially seem 
counterintuitive, given a common cyclohexyl moiety present on the relatively high affinity parent 
compound 1. This apparent discrepancy can be reconciled if the bitopic nature of 1 is taken into 
account, i.e. the high affinity of 1 is derived from concomitant salt-bridge interaction with the 
orthosteric binding site of the D2R. Without the strong ‘orthosteric anchor’ interaction, the allosteric 
fragments are more sensitive to subtle structural changes. 
Though substituent size is important for both the affinity and negative cooperativity exhibited by 
these compounds, the nature of the carboxamide NH may also be key. Both the acidity of the NH bond 
(i.e. its ability to donate a hydrogen bond) and steric crowding around the NH bond is also important. 
The N-(1-piperidyl) analogue 11s (KB = 91 µM, α = 0.30) differs from 11r only by replacement of the 
ring methine by a nitrogen atom but bears an allosteric activity profile similar to 3. Also, the N-phenyl 
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 analogue 11t (KB = 19 µM) regains affinity compared to 11r, where the saturated cyclohexyl group is 
replaced with a planar phenyl ring. In both 11s and 11t, the carboxamide NH would be expected to be a 
better hydrogen bond donor (due to substituent electron-withdrawing effect) than that of 11r. Finally, 
compounds 11u-w also support the importance of access to the carboxamide NH combined with 
sensitivity to substituent size. Insertion of a methylene spacer on 11o to give cyclopropylmethyl 
analogue 11u (KB = 30 µM, α = 0.10) improves affinity around 10-fold, as well as imparting 
determinable negative cooperativity. In comparison, no activity for 11v-w was observed up to a 
concentration of 300 µM, possibly due to these compounds bearing larger substituents causing a 
sterically unfavourable interaction with the receptor. 
Compounds 13a-e and 15 (Table 3) were based on the structure of 3, however introduced either 
fluoro- or methoxy- substituents on to the indole core. Whilst all analogues in this series retained 
activity at the D2R, the 5-fluoro analogue 13c (KB = 91 µM) and 5-methoxy analogue 15 (KB = 104 
µM) exhibited reduced affinity. In comparison the 4-fluoro analogue 13b (KB = 18 µM, α = 0.07) and 
7-fluoro analogue 13e (KB = 18 µM, α = 0.11) both displayed slightly improved affinity and displayed 
higher negative cooperativity with dopamine compared to 3. The SAR of this series is difficult to 
extrapolate without examining a wider range of compounds, though substitution at the 5- and 6-
positions of the ring appears to be less well tolerated. The effect of substitution at other ring positions is 
likely to be determined by both regional and electronic influence of each substituent. 
 
 
Table 4. Characterization of analogues of compound 3, varying the nature of the bicyclic 
heteroaromatic ring, and substitution position of the carboxamide, in terms of binding and 
function at the D2R
a
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No. Heterocycle pKB (KB, µM) Logα (α) 
3
b
 
 
4.35 ± 0.07 (45) -0.53 ± 0.09 (0.29)  
17 
 
ND ND 
19
c
 
 
5.69 ± 0.38  (2) -1.07 ± 0.22  (0.08) 
21 
 
ND ND 
23a 
 
ND ND 
23b 
 
ND ND 
25a
d
 
 
4.31 ± 0.20  (49) NA 
25b 
 
ND ND 
27 
 
ND ND 
30a 
 
ND ND 
30b
b
 
 
3.91 ± 0.5  (123) -1.27 ± 0.3  (0.05) 
30c
c
 
 
5.16 ± 0.5  (7) -1.1 ± 0.3  (0.08) 
30d 
 
ND ND 
 
aInteraction studies between compounds and dopamine were performed using an ERK1/2 
phosphorylation assay upon FlpIn CHO cells stably expressing the D2LR as in Figure 1c.  
bFor 
compounds that caused a decrease in the maximal response of dopamine, data were analysed according 
to an operational model of allosterism where KB is the equilibrium dissociation constant of the 
allosteric ligand, α is the binding cooperativity parameter between the orthosteric and allosteric ligand, 
and β (Logβ constrained to -100 to represent high negative cooperativity with dopamine efficacy) 
denotes the magnitude of the allosteric effect of the modulator on the efficacy of the orthosteric 
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 agonist. c For compounds that caused a limited rightward shift of the dopamine dose-response curve but 
no decrease in Emax, data were fit using an operational model of allosterism where Logβ was 
constrained to 0, to represent neutral cooperativity with dopamine efficacy. dFor compounds that 
produced an unlimited rightward shift of a dopamine dose-response curve within the concentration 
range of test compound used data were fit using a model of competitive antagonism (equation 6). As 
such a value of cooperativity could not be derived (denoted NA). ND signifies no effect of compound 
was observed even at the highest concentration of 300 µM. Data represent the mean ± SEM of three 
experiments performed in duplicate apart from compounds with no effect, which were tested in two 
separate experiments. 
 
In order to evaluate the importance of the indole core of 3, we also synthesized a set of analogues 
bearing alternative bicyclic heterocyclic cores (Table 4). Compounds (17, 21, 23a-b, 25b) lacking the 
ability to donate a hydrogen bond (compared to the indolic NH of 3) did not show activity up to a 
concentration of 300 µM. We were surprised to note that benzothiophene 25a (KB = 49 µM) retained 
affinity for the D2R comparable with that of 3. However, an unlimited rightward shift of the dopamine 
concentration-response curve within the concentration range of 25a employed meant a measure of 
negative cooperativity could not be determined. 
The benzimidazole based compound 19 (KB = 2 µM, α = 0.08) had both higher affinity and negative 
cooperativity relative to 3. This may be explained by the differing acidity of the indolic NH bond (pKa 
= 21)27 compared to that of benzimidazole (pKa = 16.4)
28, with the more acidic benzimidazole acting as 
a better hydrogen bond donor. 
The lack of activity exhibited by the 7-azaindole analogue 27 is somewhat surprising. However the 
ability to interact with the receptor may be complicated by a number of factors, including the complex 
interaction between the two nitrogen atoms, intermolecular dimer formation, and the ability to form 
efficient hydrogen bonds with water. 
Finally, the positional isomers 30a-d support the importance of an NH bond and relative position to 
the carboxamide moiety. Whereas 4- and 7-substituted analogues 30a and 30d were devoid of 
detectable activity, the corresponding 5- and 6-substitited analogues 30b (KB = 123 µM, α = 0.05) and 
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 30c (KB = 7 µM, α = 0.08) exhibited both affinity and negative cooperativity. Though both 30b-c 
showed a higher degree of negative cooperativity relative to 3, they were divergent in their relative 
affinities, with 30b having weaker affinity and 30c having higher affinity than 3. 
A possible explanation for the ability of 30b-c to maintain activity as negative allosteric modulators 
relative to 3, (in comparison to 30a and 30d, which are devoid of detectable activity) is that these 
regioisomers could maintain key interactions with the receptor. In particular 30c may be able to 
maintain the carboxamide-associated and indole NH-associated interactions that appear to be key to 
activity, based on our above SAR analysis. It is conceivable that 30b might not be able to participate in 
these interactions as efficiently resulting in a weaker affinity. It is clear that the position of the 
carboxamide and indolic NH within this set of regioisomers are key determinants of activity, though 
the precise nature of these interactions is yet to be determined. 
 
The activity of Compound 11d is modulated by mutation of residues within the secondary 
pocket of the D2R. We then selected 11d as the promising compound from this SAR study based upon 
both a 7-fold increase in affinity and a 10-fold increase in negative cooperativity for further 
characterization.  In particular we tested the activity of 11d at the two secondary pocket mutant D2R 
receptors Glu952.65Ala and Val912.61Ala (Figure 6, Table 5). 
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Figure 6. Mutation of residues at the top of TM2 modulates the allosteric action of 11d. Interaction 
studies between dopamine and 11d in an assay measuring D2R mediated pERK1/2 phosphorylation 
using CHO cells expressing the (a) WT, (b) Val912.61Ala or  (c) Glu952.65Ala. 
 
This compound displayed a reduced activity at the Val912.61Ala mutant, with a 14-fold decrease in 
affinity (Figure 6b, Table 5). Most likely because of this reduced affinity, while 11d did cause a 
decrease in dopamine potency at the highest concentrations used, this rightward shift did not reach a 
limit. Furthermore, in contrast to the action of the compound in this assay at the WT receptor, the Emax 
of dopamine was not reduced. Therefore, a value of negative cooperativity with dopamine binding 
affinity could not be determined for 11d. A reduced affinity at this mutant was also observed for 3 
suggesting that these compounds bind in the same secondary pocket within the D2R. Of interest, at the 
Glu952.65Ala mutant, 11d displayed similar affinity and negative cooperativity with dopamine binding, 
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 as compared to its action at the WT D2R. However, no decrease in dopamine Emax was observed, 
consistent with no modulation of dopamine efficacy. It is interesting to note that this mutation had quite 
a different effect upon the pharmacology of 3 (100-fold increase in affinity and complete loss of 
negative cooperativity with dopamine affinity). This suggests that the N-substituent attached to the 
carboxamide nitrogen (N-isopropyl in 3 compared to N-butyl in 11d) plays an important role in 
determining the effect of the mutation of Glu952.65 to alanine.  
 
 
Table 5. Characterization of the binding and function of N-butyl-1H-indole-2-carboxamide (11d) 
at the D2R
a  
 pKB  (KB, nM) Logα (α) Logβ 
Wild Type 5.21 ± 0.07  (6) -1.63 ± 0.11 (0.02) -100 
Val91
2.61
Ala 4.07 ± 0.18  (85) - - 
Glu95
2.65
Ala 5.30 ± 0.24  (5) -1.24 ± 0.17  (0.05) 0 
a The ability of 11d to modulate the functional effect of agonists or their effect at either the WT D2R 
or mutant D2Rs expressed in Flp-IN CHO cells was tested in a pERK1/2 assay and data was fit to an 
operational model of allosterism (Equation 5) to derive values of affinity (pKB) and cooperativity with 
dopamine. 
 
Given that 11d displayed 10-fold increased affinity compared to 3, we hypothesised that if we 
combined the structural features of 11d (as an allosteric moiety), with the orthosteric 7-CTHIQ head-
group, the resultant compound might exhibit a bitopic mode of interaction with the D2R in a similar 
manner to 1. Additionally, we anticipated the increased affinity displayed by the allosteric fragment 
11d might be translated into this putative bitopic ligand and confer a gain of affinity and/or negative 
cooperativity with dopamine, compared to that exhibited by 1. Accordingly we synthesised 36. This 
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 bitopic ligand displayed a 10-fold increase in affinity and similar magnitude of negative cooperativity 
with dopamine as compared to 1 (Figure 7). 
 
 
Figure 7. Incorporation of an optimized allosteric moiety (11d) into the bitopic pharmacophore of 1, to 
generate a novel bitopic ligand 36, conferring a 10-fold increase in affinity and no change in negative 
cooperativity with dopamine (pKB = 7.09 ± 0.14, Logαβ = -1.32 ± 0.09) as compared to 1. Compound 1 
binds the D2R in a bitopic mode and acts as an allosteric modulator across a D2R dimer. Compound 1 
can be separated into an orthosteric moiety (7-CTHIQ) and an allosteric moiety (3). Optimisation of 3 
yielded 11d, an allosteric modulator with 10-fold higher affinity.  Incorporation of 11d into the bitopic 
pharmacophore of 1, generated 36 that displayed 10-fold higher affinity as compared to 1. 
BITOPIC 
BITOPIC 
ORTHOSTERIC ALLOSTERIC 
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This is in line with our hypothesis and is consistent with both the allosteric moieties of 1 and 36 
occupying the same secondary pocket that includes residues extracellular at the extracellular end of 
TM2. This demonstrates that this pocket can be targeted for the development of both novel allosteric 
and bitopic ligands. It should be noted though that while 1 displays modest selectivity for the D3R, the 
allosteric fragment, 3, displayed similar affinity and allosteric action at both the D3R and D2R.  This is 
perhaps not surprising given the high homology between these two receptors and in particular that the 
two residues (Val91 and Glu95) shown to modulate the binding and/or effect of 3 and 11d are 
conserved between these two subtypes.  This suggests that the putative allosteric pocket may be very 
similar at the D2R and D3R. 
 
CONCLUSIONS 
To date, studies of bitopic ligands have been largely restricted to the muscarinic and adenosine 
receptor families.3,4 This is largely due to the rich allosteric pharmacology that exists for these two 
receptor families. Until recently, examples of small molecule allosteric modulators were lacking for the 
D2R. We previously demonstrated that 1 bound the D2R in a bitopic mode and acted as a negative 
allosteric modulator of dopamine binding and function across a D2R dimer.
13 Studies at the mAChRs 
have used ligand fragmentation approaches to isolate orthosteric and allosteric pharmacophores from a 
bitopic ligand.10,11 In this study we were able to isolate 3 an allosteric fragment of 1, derived from the 
indole-2-carboxamide moiety of the parent compound. Furthermore, we demonstrate that the action of 
3 is modulated by mutation of the same residues at the top of TM2 shown to interact with the indole-
carboxamide moiety of 1. Compound 3 bound the receptor with a relatively low affinity (48 µM) and 
displayed 4-fold lower negative cooperativity with dopamine affinity as to that observed for 1 (α = 
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 0.29). This provides further evidence of a bitopic mode of interaction for 1 at the D2R. One would 
expect a bitopic ligand to display competitive behaviour with an orthosteric agonist because the 
orthosteric head-group (in this case the 7-CTHIQ moiety) would compete to bind at the orthosteric site. 
To accommodate the bitopic binding mode of 1 with its purely allosteric pharmacology, we had to 
extend our mechanism of action to modulation across a D2R dimer. In the case of 3, this ligand 
possesses no established orthosteric pharmacophore and our mutagenesis studies suggest that it binds to 
residues within a secondary pocket at the top of TM2. Therefore, its allosteric action can be 
accommodated within a simple ternary complex of a single D2R protomer, the orthosteric agonist 
dopamine and the allosteric ligand 3. Such a mechanism of action has been validated for allosteric 
modulators of the muscarinic M2 receptor through the crystallization of such a ternary complex.
29 
However, without similar structural evidence we cannot discount that 3 or its derivatives act across a 
D2R dimer as we have shown for 1. Finally, our preliminary SAR studies of the indole-2-carboxamide 
scaffold yielded 11d an allosteric modulator that displayed a 10-fold improvement of affinity as 
compared to 3.  Furthermore, by combining this optimised allosteric moiety with the 7-CTHIQ 
orthosteric head-group of 1, we developed a novel bitopic ligand (compound 36) that displayed 10-fold 
improvement in affinity as compared to 1. If the orientation of the indole-2-carboxamide scaffold of 
11d is equivalent to that of 1, then the N-butyl substituent of 11d is equivalent to the linker region of 1. 
Therefore, the higher affinity of 36 may result from the greater flexibility of the alkyl chain linker 
allowing optimal binding of the orthosteric and allosteric moieties at their respective sites. For a bitopic 
ligand to simultaneously occupy both orthosteric and allosteric sites then these sites must proximal to 
each other and connected. It follows then that the allosteric and linker moieties will be necessarily 
integrated. Thus it is not surprising that allosteric fragments derived from bitopic ligands can be 
optimised through substitution in the direction that corresponds to the linker region. However, it is 
interesting to note that the nature of the substituent, where alkyl chains were tolerated but larger cyclic 
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 or aromatic substitutions were not, was important for maintaining the allosteric action of the fragment. 
Thus this SAR may dictate what can be tolerated or is preferable within the linker region of the bitopic 
molecule. 
 
Combined, this study reveals the indole-2-carboxamide scaffold as a novel pharmacophore for 
negative allosteric modulators of the dopamine D2R. Furthermore, this study highlights an allosteric 
pocket within the D2R between TM2 and TM7, which can be exploited for the design of novel 
allosteric modulators and bitopic ligands for this therapeutically attractive receptor.  
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 EXPERIMENTAL SECTION 
Chemistry. Chemicals and solvents were purchased from standard suppliers and used without further 
purification.  Davisil® silica gel (40-63µm), for flash column chromatography (FCC) was supplied by 
Grace Davison Discovery Sciences (Victoria, Australia) and deuterated solvents were purchased from 
Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem Pty Ltd, Victoria, Australia). 
Unless otherwise stated, reactions were carried out at ambient temperature. All microwave reactions 
took place in a Biotage Initiator Microwave Synthesiser. Reactions were monitored by thin layer 
chromatography on commercially available precoated aluminium-backed plates (Merck Kieselgel 60 
F254). Visualisation was by examination under UV light (254 and 366 nm). General staining carried out 
with KMnO4 or phosphomolybdic acid. A solution of Ninhydrin (in ethanol) was used to visualize 
primary and secondary amines. All organic extracts collected after aqueous work-up procedures were 
dried over anhydrous MgSO4 or Na2SO4 before gravity filtering and evaporation to dryness. Organic 
solvents were evaporated in vacuo at ≤ 40°C (water bath temperature).  Purification using preparative 
layer chromatography (PLC) was carried out on Analtech preparative TLC plates (200 mm × 200 mm 
× 2 mm). 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance Nanobay III 400MHz Ultrashield 
Plus spectrometer at 400.13 MHz and 100.62 MHz respectively. Chemical shifts (δ) are recorded in 
parts per million (ppm) with reference to the chemical shift of the deuterated solvent. Coupling 
constants (J) and carbon-fluorine coupling constants (JCF) are recorded in Hz and the significant 
multiplicities described by singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), multiplet (m), 
doublet of doublets (dd), doublet of triplets (dt). Spectra were assigned using appropriate COSY, 
distortionless enhanced polarisation transfer (DEPT), HSQC and HMBC sequences. 
Analytical reverse-phase HPLC was performed on a Waters HPLC system coupled directly to a 
photodiode array detector and fitted with a Phenomenex® Luna C8(2) 100 Å column (150 mm × 4.6 
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 mm, 5 µm) using a binary solvent system; solvent A: 0.1% TFA/H2O; solvent B: 0.1% TFA/80% 
CH3CN/H2O. Gradient elution was achieved using 100% solvent A to 100% solvent B over 20 min at a 
flow rate of 1 mL/min. 
LCMS were run to verify reaction outcome and purity using either system A or B. System A: an 
Agilent 6100 Series Single Quad coupled to an Agilent 1200 Series HPLC. The following buffers were 
used; buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in MeCN. The following gradient 
was used with a Phenomenex Luna 3µM C8 (2) 15 × 4.6 mm column, and a flow rate of 0.5 mL/min 
and total run time of 12 min; 0–4 min 95% buffer A and 5% buffer B, 4–7 min 0% buffer A and 100% 
buffer B, 7–12 min 95% buffer A and 5% buffer B. Mass spectra were acquired in positive and 
negative ion mode with a scan range of 0–1000 m/z at 5V. UV detection was carried out at 254 nm. 
System B: an Agilent 6120 Series Single Quad coupled to an Agilent 1260 Series HPLC. The 
following buffers were used; buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in MeCN.  
The following gradient was used with a Poroshell 120 EC-C18 50 × 3.0 mm 2.7 micron column, and a 
flow rate of 0.5 mL/min and total run time of 5 min; 0–1 min 95% buffer A and 5% buffer B, from 1-
2.5 min up to 0% buffer A and 100% buffer B, held at this composition until 3.8 min, 3.8–4 min 95% 
buffer A and 5% buffer B, held until 5 min at this composition. Mass spectra were acquired in positive 
and negative ion mode with a scan range of 100–1000 m/z. UV detection was carried out at 214 and 
254 nm. All retention times (tR) are quoted in min. High resolution mass spectra (HRMS) were 
obtained on a Waters LCT Premier XE (TOF) using electrospray ionization (ESI) at a cone voltage of 
50 V. All tested compounds were of > 95% purity. 
General Procedure A: Substituted 1H-indole-2-carboxamide synthesis through direct 
aminolysis of methyl 1H-indole-2-carboxylate. Methyl 1H-indole-2-carboxylate (10) (100 mg, 0.57 
mmol) was dispersed in EtOH (1 mL) at rt. To this was added either neat amine or a solution of amine 
(1 mL) and stirring continued until TLC analysis (EtOAc/PE 3:7) indicated ester had been consumed. 
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 The mixture was diluted with water and the resulting precipitate collected by filtration (vacuum) and 
washed with water. Where necessary, further purification was achieved by FCC (see individual 
monographs). 
General procedure B: HCTU-mediated coupling of carboxylic acids with amines in DMF 
(using excess amine as base). Carboxylic acid and HCTU (1.1 eq) were dissolved in DMF (1 mL) 
with stirring at rt. To this was added amine (2.5-3 eq), and mixture stirred at rt overnight. TLC analysis 
(EtOAc/PE 1:1 or EtOAc) was used to confirm reaction completion after this period. The mixture was 
diluted with water (10 mL) and allowed to stir at rt for 10 min, before collecting the resultant 
precipitate by filtration (vacuum), then washing with water. Further purification was achieved by 
aqueous workup and FCC as detailed under each monologue. 
General procedure C: Ester hydrolysis of methyl indole carboxylates with LiOH.H2O. Ester 
(100 mg, 0.57 mmol) and LiOH.H2O (72 mg, 1.71 mmol, 3 eq) was stirred in THF/water (1:1, 2 mL) at 
rt for 90 h. LCMS analysis after this time indicated complete hydrolysis had taken place. The mixture 
was diluted with water (20 mL) and washed with Et2O (20 mL). After discarding the Et2O washings, 
the aqueous layer was acidified with 2 M HCl(aq) to pH~2. The aqueous layer was then extracted with 
EtOAc (3 × 20 mL), and the combined organic extracts washed with brine (20 mL). On concentration, 
the desired carboxylic acid was obtained, requiring no further purification. 
N-Isopropyl-1H-indole-2-carboxamide (3).
30
 Indole-2-carboxylic acid (1) (1.00 g, 6.21 mmol) and 
HCTU (2.82 g, 6.82 mmol, 1.1 eq) were dissolved in DMF (10 mL) at rt with stirring. To this was 
added isopropylamine (1.59 mL, 18.6 mmol, 3 eq), and the mixture stirred at rt overnight. TLC analysis 
(EtOAc/PE 1:1) indicated complete conversion, so the reaction was quenched with water (100 mL), 
and the resulting precipitate collected by filtration (vacuum). After drying, the precipitate was further 
purified by FCC (eluent EtOAc/PE 0:100 to 30:70), to give 940 mg of white solid (75%). 1H NMR (d6-
DMSO) δ 11.50 (s, 1H), 8.20 (d, J = 7.8 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.41 (dd, J = 8.2/0.8 Hz, 
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 1H), 7.23–7.08 (m, 2H), 7.02 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 4.28–3.94 (m, 1H), 1.19 (d, J = 6.6 Hz, 
6H); 13C NMR (d6-DMSO) δ 160.2, 136.3, 132.0, 127.1, 123.1, 121.4, 119.6, 112.2, 102.4, 40.6, 22.4; 
m/z MS (TOF ES+) C12H15N2O [MH]
+ calcd 203.1; found 203.1; LCMS tR: 3.20 min (system B). 
Ethyl 2-((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)acetate (5). 2-((trans)-4-((tert-
butoxycarbonyl)amino)cyclohexyl)acetic acid (4) (1.00 g, 3.89 mmol) and K2CO3 (644 mg, 4.66 mmol, 
1.2 eq) were dispersed in MeCN (30 mL). To this was added EtI (0.344 mL, 4.28 mmol, 1.1 eq), and 
the mixture stirred at rt for 1.75 h. LCMS analysis indicated no progress, and the mixture had formed a 
gel, so MeCN (20 mL) was added, and the mixture heated under reflux for 3 h. EtI (0.156 mL, 1.95 
mmol, 0.5 eq) was added and the mixture heated at 50 °C overnight. LCMS analysis indicated almost 
complete conversion, so EtI (0.156 mL, 1.95 mmol, 0.5 eq) was added and the mixture heated under 
reflux for 2 h. The mixture was cooled, and concentrated under reduced pressure to remove MeCN and 
EtI. The residue was taken up into EtOAc (30 mL) and washed with water (30 mL), sat. NaHCO3 (aq) 
(30 mL) and brine (30 mL). After concentration, 1.11 g of white solid was obtained (quantitative yield). 
1H NMR (CDCl3) δ 4.60–4.19 (m, 1H), 4.19–3.98 (m, 2H), 3.37 (s, 1H), 2.18 (d, J = 6.8 Hz, 2H), 1.98 
(dd, J = 14.1/9.4 Hz, 2H), 1.87–1.55 (m, 3H), 1.43 (s, 9H), 1.33–1.21 (m, 3H), 1.19–0.98 (m, 4H); 13C 
NMR (CDCl3) δ 173.0, 155.4, 79.2, 60.4, 49.7, 41.6, 34.2, 33.3, 31.7, 28.6, 14.4; m/z MS (TOF ES
+) 
C15H27NNaO4 [MNa]
+ calcd 308.2; found 308.2; LCMS tR: 3.40 min (system B). 
tert-Butyl ((trans)-4-(2-oxoethyl)cyclohexyl)carbamate (6). Ethyl 2-((trans)-4-((tert-
butoxycarbonyl)amino)cyclohexyl)acetate (5) (1.059 g, 3.71 mmol) was dissolved in dry toluene (15 
mL) under an atmosphere of N2. The reaction mixture was degassed with a stream of N2, before 
cooling to -78 °C (dry ice/acetone). DIBAL-H in toluene (1M, 7.5 mL, ~2 eq) was added, and the 
mixture maintained at -78 °C with stirring for 3.5 h (TLC analysis (EtOAc/PE 3:7) after 1.5 h indicated 
complete consumption of starting material). The mixture was quenched with care using MeOH (7.5 
mL), whilst maintaining the temperature at -78 °C. After complete addition of MeOH, the mixture was 
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 warmed to rt, then stirred for 15 min, before addition of saturated potassium sodium tartrate 
(Rochelle’s salt) solution (35 mL), and continuing stirring at rt for a further 30 min. The reaction 
mixture was then extracted with Et2O (4 × 30 mL), and the combined organic extracts concentrated 
under reduced pressure, to give 913 mg of white solid (quantitative yield). 1H NMR (CDCl3) δ 9.75 (t, 
J = 2.0 Hz, 1H), 4.36 (s, 1H), 3.37 (s, 1H), 2.32 (dd, J = 6.6/2.0 Hz, 2H), 2.10–1.92 (m, 2H), 1.91–1.70 
(m, 3H), 1.43 (s, 9H), 1.22–0.99 (m, 4H); 13C NMR (CDCl3) δ 202.3, 155.4, 79.2, 50.8, 49.6, 33.3, 
31.9, 31.8, 28.6; m/z MS (TOF ES+) C9H16NO3 [M+2H-
tBu]+ calcd 186.1; found 186.2; LCMS tR: 6.70 
min (system A). 
tert-Butyl ((trans)-4-(2-(dimethylamino)ethyl)cyclohexyl)carbamate hydrochloride (7a). tert-
Butyl ((trans)-4-(2-oxoethyl)cyclohexyl)carbamate (6) (165 mg, 0.68 mmol) was dissolved in 1,2-
dichloroethane (3 mL) with stirring at rt, before adding N,N-dimethylamine hydrochloride (56 mg, 0.68 
mmol, 1 eq) and Na(OAc)3BH (219 mg, 1.03 mmol, 1.5 eq). The mixture was stirred under an inert 
atmosphere for 16 h at rt, after which LCMS analysis indicated the reaction was complete. The mixture 
was then diluted with DCM (15 mL), before washing with 1 M K2CO3 (aq) (3 × 20 mL) and brine (15 
mL). The DCM layer was then dried over anhydrous Na2SO4 before concentration under reduced 
pressure. The crude residue was purified by FCC (eluent MeOH/CHCl3 2:8) to give the desired 
compound in the free-amine form as a clear oil (105 mg, 50%). 1H NMR (400 MHz, CDCl3) δ 4.39 (br 
s, 1H), 3.70–3.62 (m, 3H), 3.37 (br s, 1H), 2.04–1.96 (m, 2H), 1.82–1.72 (m, 2H), 1.65–1.28 (m, 17H), 
1.14–0.97 (m, 4H). 13C NMR (CDCl3) δ 155.4, 79.1, 57.6, 50.5, 45.2, 35.2, 34.2, 33.4, 32.0, 28.5. m/z 
MS (TOF ES+) C15H31N2O2 [MH]
+ calcd 271.2; found 271.2; LCMS: no visible UV absorbance at 254 
nm. 
The free-amine product was then converted to the hydrochloride salt by taking up in CHCl3 (10 mL), 
before adding 1 M HCl/Et2O, and then solvents removed to give a colourless solid. 
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 tert-Butyl ((trans)-4-(2-(dipropylamino)ethyl)cyclohexyl)carbamate (7b). tert-Butyl ((trans)-4-(2-
oxoethyl)cyclohexyl)carbamate (6) (170 mg, 0.70 mmol) was dissolved in 1,2-dichloroethane (3 mL) 
with stirring at rt, before adding N,N-dipropylamine (71 mg, 0.70 mmol, 1 eq) and NaBH(OAc)3 (223 
mg, 1.05 mmol, 1.5 eq). The mixture was stirred under an inert atmosphere for 16 h at rt, after which 
LCMS analysis indicated the reaction was complete. The mixture was then diluted with DCM (15 mL), 
before washing with 1M K2CO3 (aq) (3 × 20 mL) and brine (15 mL). The DCM layer was then dried 
over anhydrous Na2SO4 before concentration under reduced pressure. The crude residue was purified 
by FCC (eluent MeOH/CHCl3 2:8) to give the desired compound as a clear oil (128 mg, 56%). 
1H 
NMR (CDCl3) δ 4.39 (br s, 1H), 3.36 (br s, 1H), 2.46–2.39 (m, 2H), 2.39–2.30 (m, 4H), 2.02–1.92 (m, 
2H), 1.78–1.71 (m, 2H), 1.50–1.39 (m, 13H), 1.36–1.30 (m, 2H), 1.22–1.18 (m, 1H), 1.11–0.97 (m, 
4H), 0.87 (dd, J = 9.3/5.4 Hz, 2 × 3H); 13C NMR (CDCl3) δ 155.4, 79.1, 56.3, 51.9, 50.0, 35.4, 33.8, 
33.6, 32.1, 28.5, 20.2, 12.1; 
(trans)-4-(2-(Dimethylammonio)ethyl)cyclohexan-1-aminium di-(2,2,2-trifluoroacetate) (8a). 
tert-Butyl ((trans)-4-(2-(dimethylamino)ethyl)cyclohexyl)carbamate hydrochloride (7a) (105 mg, 0.34 
mmol) was taken up in DCM (3 mL) and TFA (1 mL), and the colourless solution allowed to stir at rt 
for 15 min. The solvents were then evaporated to dryness under reduced pressure, to give the title 
compound as a colourless oil (quantitative yield). 1H NMR (MeOD) δ 3.10–3.02 (m, 2H), 3.01–2.90 
(m, 1H), 2.77 (s, 6H), 2.04–1.90 (m, 2H), 1.85–1.72 (m, 2H), 1.59–1.49 (m, 2H), 1.39–1.22 (m, 3H), 
1.12–0.96 (ddd, J = 25.3/13.3/3.2 Hz, 2H); 13C NMR (MeOD) δ 162.7 (q, JCF = 34.9 Hz), 116.0 (q, JCF 
= 284 Hz), 57.1, 51.3, 43.4, 35.2, 31.9, 31.5, 31.4. 
(trans)-4-(2-(Dipropylammonio)ethyl)cyclohexan-1-aminium di-(2,2,2-trifluoroacetate) (8b). 
tert-Butyl ((trans)-4-(2-(dipropylamino)ethyl)cyclohexyl)carbamate (7b) (128 mg, 0.39 mmol) was 
taken up in DCM (3 mL) and TFA (1 mL), and the colourless solution allowed to stir at rt for 15 min. 
The solvents were then evaporated to dryness under reduced pressure, to give the title compound as a 
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 colourless oil (85 mg, 96%). 1H NMR (MeOD) δ 3.22–3.13 (m, 2H), 3.13–3.01 (m, 5H), 2.12–2.01 (m, 
2H), 1.95–1.85 (m, 2H), 1.80–1.68 (m, 4H), 1.68–1.59 (m, 2H), 1.49–1.32 (m, 3H), 1.22–1.08 (m, 2H), 
1.01 (t, J = 7.4 Hz, 2 × 3H). 13C NMR (MeOD) δ 161.5 (q, JCF = 37.5 Hz), 117.4 (q, JCF = 289 Hz), 
55.6, 52.4, 51.3, 35.4, 31.5, 31.4, 31.0, 18.3, 11.1. 
 N-((trans)-4-(2-(Dimethylamino)ethyl)cyclohexyl)-1H-indole-2-carboxamide hydrochloride 
(9a). (trans)-4-(2-(Dimethylamino)ethyl)cyclohexan-1-amine (8a) (60 mg, 0.35 mmol) and indole-2-
carboxylic acid (2) (114 mg, 0.71 mmol, 2 eq) were taken up in DCM (5 mL) before DIPEA (1.23 mL, 
7.05 mmol, 10 eq), and BOP (234 mg, 0.53 mmol, 1.5 eq) were added. The clear yellow solution turned 
cloudy after 5 min of stirring at rt, and after 1 h, the reaction was complete by LCMS analysis. The 
reaction mixture was then diluted with DCM (20 mL), washed with 1 M K2CO3 (aq) (2 × 20 mL), brine 
(20 mL), dried over anhydrous Na2SO4, then evaporated to dryness. The resulting crude solid was 
recrystallised from MeOH/water to give the product as a pale yellow solid, which was then converted 
to the hydrochloride salt in 1 M HCl solution, then lyophilized to give the title compound as a pale 
yellow solid (44 mg, 36%). Mp: 271–273 °C; 1H NMR (d6-DMSO) δ 11.54 (s, 1H) 10.49 (s, 1H), 8.31 
(d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.42 (dd, J = 8.2/0.7 Hz, 1H), 7.19–7.13 (m, 2H), 7.05–
6.99 (t, J = 7.9 Hz, 1H), 3.77 (dtt, J = 15.4/7.8/3.8 Hz, 1H), 3.10–2.99 (m, 2H), 2.71 (s, 6H), 1.88 (d, J 
= 10.1 Hz, 2H), 1.77 (d, J = 11.8 Hz, 2H), 1.62–1.54 (m, 2H), 1.45–1.25 (m, 3H), 1.14–0.98 (m, 2H); 
13C NMR (d6-DMSO) δ 160.2, 136.3, 132.0, 127.0, 123.1, 121.4, 119.6, 112.2, 102.7, 54.8, 48.0, 41.9, 
34.2, 32.0, 31.2, 30.4; LCMS tR: 4.66 min (system A); HPLC (λ = 254, 214 nm) tR = 7.99 min; HRMS 
(m/z): [MH]+ calcd. for C19H27N3O, 314.2227; found 314.2228. 
N-((trans)-4-(2-(Dipropylamino)ethyl)cyclohexyl)-1H-indole-2-carboxamide (9b). (trans)-4-(2-
(Dipropylamino)ethyl)cyclohexan-1-amine (8b) (85 mg, 0.38 mmol) was taken up in DCM (5 mL) 
before DIPEA (0.653 mL, 3.75 mmol, 10 eq), BOP (252 mg, 0.57 mmol, 1.5 eq)  and indole-2-
carboxylic acid (2) (61 mg, 0.38 mmol, 1eq) were added. The yellow solution was allowed to stir at rt 
Page 44 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 for 4 h, after which time a precipitate formed and was collected by filtration to afford the title 
compound as a white solid. The filtrate was then concentrated to effect further solid precipitation, 
which was collected by filtration and washed with methanol (5 mL), to give a second crop of the title 
compound as a white solid (45 mg, 49%). Mp: 226–228 °C; 1H NMR (d6-DMSO) δ 11.49 (s, 1H), 8.17 
(d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.19–7.11 (m, 2H), 7.02 (t, J = 
7.5 Hz, 1H), 3.82–3.67 (m, 1H), 2.59–2.27 (m, 6H), 1.87 (d, J = 11.4 Hz, 2H), 1.77 (d, J = 12.1 Hz, 
2H), 1.48–1.18 (m, 9H), 1.10–0.93 (m, 2H), 0.85 (t, J = 7.3 Hz, 6H); 13C NMR (d6-DMSO) δ 160.2, 
136.3, 132.0, 127.1, 123.1, 121.4, 119.6, 112.2, 102.4, 55.3, 51.1, 48.2, 34.6, 33.4, 32.4, 31.7, 19.6, 
11.7; LCMS tR: 4.82 min (system A); HPLC (λ = 214 nm) tR = 9.01 min; HRMS (m/z): [MH]
+ calcd. 
for C23H35N3O, 370.2853; found 370.2871.  
Methyl 1H-indole-2-carboxylate (10). Indole-2-carboxylic acid (2) (1.038 g, 6.44 mmol) was 
dissolved in MeOH (30 mL), and concentrated sulfuric acid (0.5 mL) added. The mixture was heated 
under reflux for 5.75 h, then stirred at rt overnight. TLC analysis (EtOAc/PE 1:1) indicated almost 
complete conversion, so reflux was continued for a further 7 h. The mixture was concentrated, and the 
residue dispersed in sat. NaHCO3 (aq), causing a beige solid to precipitate. This was collected by 
filtration (vacuum) and washed with water before drying, to give 1.101 g (98%) of beige solid. 1H 
NMR (CDCl3) δ 8.92 (s, 1H), 7.70 (dd, J = 8.1/0.9 Hz, 1H), 7.43 (dd, J = 8.3/0.9 Hz, 1H), 7.33 (ddd, J 
= 8.3/7.0/1.1 Hz, 1H), 7.23 (dd, J = 2.1/0.9 Hz, 1H), 7.16 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 3.96 (s, 3H); 
13C NMR (CDCl3) δ 162.6, 137.0, 127.6, 127.3, 125.6, 122.8, 121.0, 112.0, 109.0, 52.2; m/z MS (TOF 
ES+) C10H10NO2 [MH]
+ calcd 176.1; found 176.1; LCMS tR: 3.60 min (system B) 
1H-Indole-2-carboxamide (11a). The title compound was synthesised according to general 
procedure A, using NH4OH(aq). After stirring for 2 nights, further NH4OH(aq) (2 mL) was added, and 
stirring continued for a further 4 nights. The compound was isolated as 61 mg of white solid (67%). 1H 
NMR (d6-DMSO) δ 11.51 (s, 1H), 7.93 (s, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.41 (dd, J = 8.2/0.8 Hz, 1H), 
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 7.33 (s, 1H), 7.17 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.11 (d, J = 1.3 Hz, 1H), 7.02 (ddd, J = 8.0/7.0/1.0 Hz, 
1H); 13C NMR (d6-DMSO) δ 162.8, 136.5, 131.8, 127.1, 123.2, 121.5, 119.6, 112.3, 103.0; m/z MS 
(TOF ES+) C9H9N2O [MH]
+ calcd 161.1; found 161.1; LCMS tR: 2.93 min (system B). 
N-Ethyl-1H-indole-2-carboxamide (11b).
31
 The title compound was synthesised according to 
general procedure A, initially using 33% EtNH2 in EtOH. After overnight stirring, TLC analysis 
indicated minimal progress, so 70% EtNH2 (aq) (2 mL) was added, and stirring continued for a further 2 
nights. After diluting with water, the crude precipitate was collected and further purified by FCC 
(eluent MeOH/DCM 0:100 to 5:95), to give 45 mg of white solid (42%); 1H NMR (CDCl3) δ 9.34 (s, 
1H), 7.65 (d, J = 8.0 Hz, 1H), 7.44 (dd, J = 8.3/0.8 Hz, 1H), 7.29 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.14 
(ddd, J = 8.0/7.0/1.0 Hz, 1H), 6.82 (d, J = 1.1 Hz, 1H), 6.17 (s, 1H), 3.55 (td, J = 10.7/7.1 Hz, 2H), 
1.29 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3) δ 160.9, 139.6, 137.3, 127.9, 124.6, 122.0, 120.8, 112.1, 
101.7, 34.8, 15.2; m/z MS (TOF ES+) C11H13N2O [MH]
+ calcd 189.1; found 189.1; LCMS tR: 3.12 min 
(system B). 
N-Propyl-1H-indole-2-carboxamide (11c).
32
 The title compound was synthesised according to 
general procedure A, using n-propylamine. After stirring for 2 nights, further n-propylamine (2 mL) 
was added, and stirring continued for a further 4 nights. After diluting with water, the crude precipitate 
was collected and further purified by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 87 mg of white 
solid (76%); 1H NMR (d6-DMSO) δ 11.52 (s, 1H), 8.44 (t, J = 5.7 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 
7.41 (dd, J = 8.2/0.8 Hz, 1H), 7.16 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.10 (dd, J = 2.1/0.7 Hz, 1H), 7.02 
(ddd, J = 8.0/7.0/1.0 Hz, 1H), 3.29–3.17 (m, 2H), 1.63–1.46 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H); 13C 
NMR (d6-DMSO) δ 161.0, 136.3, 131.9, 127.1, 123.1, 121.4, 119.6, 112.2, 102.2, 40.5, 22.5, 11.4; m/z 
MS (TOF ES+) C12H15N2O [MH]
+ calcd 203.1; found 203.2; LCMS tR: 3.23 min (system B). 
N-Butyl-1H-indole-2-carboxamide (11d).
31
 The title compound was synthesised according to 
general procedure A, using n-butylamine. After stirring for 2 nights, further n-butylamine (2 mL) was 
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 added, and stirring continued for a further 4 nights. After diluting with water, the crude precipitate was 
collected and further purified by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 62 mg of white solid 
(50%); 1H NMR (d6-DMSO) δ 11.51 (s, 1H), 8.41 (t, J = 5.6 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.41 
(dd, J = 8.2/0.8 Hz, 1H), 7.16 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.09 (d, J = 1.4 Hz, 1H), 7.02 (ddd, J = 
8.0/7.1/0.9 Hz, 1H), 3.28 (dt, J = 6.9/6.9 Hz, 2H), 1.59–1.46 (m, 2H), 1.41–1.28 (m, 2H), 0.91 (t, J = 
7.3 Hz, 3H); 13C NMR (d6-DMSO) δ 161.0, 136.3, 131.9, 127.1, 123.1, 121.4, 119.6, 112.2, 102.1, 
38.4, 31.4, 19.6, 13.7; m/z MS (TOF ES+) C13H17N2O [MH]
+ calcd 217.1; found 217.2; LCMS tR: 3.34 
min (system B). 
N-Allyl-1H-indole-2-carboxamide (11e).
33
 The title compound was synthesised according to 
general procedure A, using allylamine. After stirring for 2 nights, further allylamine (2 mL) was added. 
Stirring was continued for a further 7 nights, before adding in allylamine (2 mL) and stirring over the 
weekend. After diluting with water, the crude precipitate was collected and further purified by FCC 
(eluent EtOAc/PE 0:100 to 30:70), to give 41 mg of white solid (36%); 1H NMR (d6-DMSO) δ 11.56 
(s, 1H), 8.66 (t, J = 5.7 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.42 (dd, J = 8.2/0.8 Hz, 1H), 7.27–7.10 (m, 
2H), 7.03 (ddd, J = 8.0/7.0/0.9 Hz, 1H), 5.92 (ddt, J = 17.2/10.3/5.2 Hz, 1H), 5.20 (ddt, J = 17.2/1.7/1.7 
Hz, 1H), 5.11 (ddt, J = 10.3/1.6/1.6 Hz, 1H), 4.02–3.85 (m, 2H); 13C NMR (d6-DMSO) δ 160.9, 136.4, 
135.5, 131.6, 127.1, 123.2, 121.5, 119.7, 115.2, 112.3, 102.4, 41.0; m/z MS (TOF ES+) C12H13N2O 
[MH]+ calcd 201.1; found 201.1; LCMS tR: 3.12 min (system B). 
N-(2-Hydroxyethyl)-1H-indole-2-carboxamide (11f).
34
 The title compound was synthesised 
according to general procedure A, using ethanolamine. After stirring for 2 nights, the mixture was 
diluted with water. The crude precipitate was collected and further purified by FCC (eluent 
MeOH/DCM 0:100 to 5:95), to give 42 mg of white solid (36%); 1H NMR (d6-DMSO) δ 11.54 (s, 1H), 
8.44 (t, J = 5.6 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.41 (dd, J = 8.2/0.7 Hz, 1H), 7.16 (ddd, J = 
8.2/7.0/1.1 Hz, 1H), 7.11 (d, J = 1.4 Hz, 1H), 7.07–6.96 (m, 1H), 4.76 (t, J = 5.5 Hz, 1H), 3.53 (q, J = 
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 6.1 Hz, 2H), 3.41–3.34 (m, 2H); 13C NMR (d6-DMSO) δ 161.2, 136.4, 131.8, 127.1, 123.2, 121.4, 
119.6, 112.3, 102.4, 59.9, 41.7; m/z MS (TOF ES+) C11H13N2O2 [MH]
+ calcd 205.1; found 205.1; 
LCMS tR: 2.91 min (system B). 
N-(Pentan-3-yl)-1H-indole-2-carboxamide (11g). Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to 1-ethylpropylamine according to general procedure B. The crude precipitate was 
dissolved in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and 
further purifying the residue by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 116 mg of white solid 
(76%). 1H NMR (d6-DMSO) δ 11.49 (s, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.68–7.52 (m, 1H), 7.42 (dd, J = 
8.2/0.8 Hz, 1H), 7.26–7.09 (m, 2H), 7.02 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 3.81 (dtt, J = 8.6/8.6/5.1 Hz, 
1H), 1.64–1.40 (m, 4H), 0.88 (t, J = 7.4 Hz, 2 × 3H); 13C NMR (d6-DMSO) δ 160.9, 136.3, 132.0, 
127.1, 123.1, 121.3, 119.6, 112.2, 102.3, 51.7, 27.0, 10.6; m/z MS (TOF ES+) C14H19N2O [MH]
+ calcd 
231.2; found 231.2; LCMS tR: 3.36 min (system B). 
N-(tert-Butyl)-1H-indole-2-carboxamide (11h).
32
 Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to tert-butylamine according to general procedure B. The crude precipitate was dissolved 
in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and further 
purifying the residue by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 89 mg of white solid (66%). 
1H NMR (d6-DMSO) δ 11.45 (s, 1H), 7.71 (s, 1H), 7.58 (dd, J = 7.9/0.6 Hz, 1H), 7.41 (dd, J = 8.2/0.8 
Hz, 1H), 7.23–7.09 (m, 2H), 7.01 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 1.41 (s, 9H); 13C NMR (d6-DMSO) δ 
160.8, 136.2, 132.6, 127.1, 123.1, 121.3, 119.6, 112.1, 102.7, 50.8, 28.7; m/z MS (TOF ES+) 
C13H17N2O [MH]
+ calcd 217.1; found 217.2; LCMS tR: 3.35 min (system B). 
N,N-Dimethyl-1H-indole-2-carboxamide (11i). The title compound was synthesised according to 
general procedure A, using 40% Me2NH(aq). After stirring for 2 nights, further Me2NH(aq) (2 mL) was 
added, and stirring continued for a further 4 nights. After diluting with water, the crude precipitate was 
collected and further purified by FCC (eluent EtOAc/PE 20:80 to 100:0), to give 36 mg of white solid 
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 (34%). 1H NMR (d6-DMSO) δ 11.51 (s, 1H), 7.61 (dd, J = 7.9/0.8 Hz, 1H), 7.42 (dd, J = 8.2/0.9 Hz, 
1H), 7.18 (ddd, J = 8.2/7.0/1.2 Hz, 1H), 7.03 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 6.87 (dd, J = 2.2/0.8 Hz, 
1H), 3.65–2.83 (m, 6H); 13C NMR (d6-DMSO) δ 162.6, 135.7, 130.2, 127.0, 123.2, 121.4, 119.6, 
112.1, 104.6, 38.89; m/z MS (TOF ES+) C11H13N2O [MH]
+ calcd 189.1; found 189.1; LCMS tR: 3.14 
min (system B). 
N,N-Diisopropyl-1H-indole-2-carboxamide (11j).
35
 Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to diisopropylamine according to general procedure B. The crude precipitate was 
dissolved in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and 
further purifying the residue by FCC (eluent EtOAc/PE 0:100 to 50:50, then recolumn in MeOH/DCM 
0:100 to 5:95), to give 52 mg of white solid (34%). 1H NMR (d6-DMSO) δ 11.50 (s, 1H), 7.58 (d, J = 
7.9 Hz, 1H), 7.38 (dd, J = 8.2/0.8 Hz, 1H), 7.15 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.02 (ddd, J = 
7.9/7.1/0.9 Hz, 1H), 6.60 (d, J = 1.4 Hz, 1H), 4.12 (s, 2H), 1.34 (d, J = 6.0 Hz, 12H); 13C NMR (d6-
DMSO) δ 162.6, 137.4, 135.6, 132.2, 122.6, 121.1, 119.6, 111.8, 101.3, 52.2, 20.7; m/z MS (TOF ES+) 
C15H21N2O [MH]
+ calcd 245.2; found 245.1; LCMS tR: 3.52 min (system B). 
Azetidin-1-yl(1H-indol-2-yl)methanone (11k). Indole-2-carboxylic acid (100 mg, 0.62 mmol) was 
coupled to azetidine according to general procedure B. The crude precipitate was further purified by 
FCC (eluent EtOAc/PE 0:100 to 100:0) to give a white solid (contaminated with 6-chloro-1H-
benzo[d][1,2,3]triazol-1-ol). This was dissolved in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) 
(30 mL) and brine (30 mL), before concentrating to give 47 mg of white solid (38%); 1H NMR (d6-
DMSO) δ 11.57 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.43 (dd, J = 8.2/0.7 Hz, 1H), 7.19 (ddd, J = 
8.2/7.0/1.1 Hz, 1H), 7.04 (ddd, J = 7.9/7.2/0.9 Hz, 1H), 6.79 (d, J = 1.4 Hz, 1H), 4.51 (t, J = 7.1 Hz, 
2H), 4.09 (t, J = 7.2 Hz, 2H), 2.43–2.23 (m, 2H); 13C NMR (d6-DMSO) δ 161.5, 135.9, 129.3, 127.4, 
123.5, 121.6, 119.7, 112.3, 104.2, 52.5, 48.5, 15.9; m/z MS (TOF ES+) C12H13N2O [MH]
+ calcd 201.1; 
found 201.1; LCMS tR: 3.16 min (system B). 
Page 49 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  (1H-Indol-2-yl)(pyrrolidin-1-yl)methanone (11l).
36
 Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to pyrrolidine according to general procedure B. The crude precipitate was further purified 
by FCC (eluent EtOAc/PE 0:100 to 100:0) to give a white solid (contaminated with 6-chloro-1H-
benzo[d][1,2,3]triazol-1-ol). This was dissolved in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) 
(30 mL) and brine (30 mL), before concentrating to give 87 mg of white solid (65%). 1H NMR (d6-
DMSO) δ 11.52 (s, 1H), 7.62 (dd, J = 7.9/0.6 Hz, 1H), 7.44 (dd, J = 8.2/0.8 Hz, 1H), 7.18 (ddd, J = 
8.2/7.0/1.1 Hz, 1H), 7.03 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 6.95 (d, J = 1.5 Hz, 1H), 3.82 (t, J = 6.6 Hz, 
2H), 3.55 (t, J = 6.8 Hz, 2H), 2.10–1.92 (m, 2H), 1.93–1.79 (m, 2H); 13C NMR (d6-DMSO) δ 160.3, 
135.8, 131.1, 127.4, 123.4, 121.6, 119.6, 112.2, 104.5, 48.0, 47.0, 26.2, 23.5; m/z MS (TOF ES+) 
C13H15N2O [MH]
+ calcd 215.1; found 215.1; LCMS tR: 3.27 min (system B). 
 (1H-Indol-2-yl)(piperidin-1-yl)methanone (11m).
37
 Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to piperidine according to general procedure B. The crude precipitate was further purified 
by FCC (eluent EtOAc/PE 0:100 to 50:50) to give a white solid (contaminated with 6-chloro-1H-
benzo[d][1,2,3]triazol-1-ol). This was dissolved in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) 
(30 mL) and brine (30 mL), before concentrating to give 112 mg of white solid (79%). 1H NMR (d6-
DMSO) δ 11.53 (s, 1H), 7.60 (dd, J = 7.9/0.6 Hz, 1H), 7.41 (dd, J = 8.2/0.8 Hz, 1H), 7.17 (ddd, J = 
8.2/7.0/1.1 Hz, 1H), 7.03 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 6.73 (dd, J = 2.1/0.7 Hz, 1H), 3.70 (s, 4H), 
1.86–1.38 (m, 6H); 13C NMR (d6-DMSO) δ 161.9, 135.8, 130.3, 126.8, 123.0, 121.2, 119.6, 112.0, 
103.3, 47.1, 25.8, 24.1; m/z MS (TOF ES+) C14H17N2O [MH]
+ calcd 229.1; found 229.1; LCMS tR: 
3.37 min (system B). 
(1H-Indol-2-yl)(morpholino)methanone (11n).
38
 Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to morpholine according to general procedure B. The crude precipitate was dissolved in 
EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and further purifying 
the residue by FCC (eluent EtOAc/PE 10:90 to 100:0), to give 107 mg of white solid (75%). 1H NMR 
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 (d6-DMSO) δ 11.58 (s, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.42 (dd, J = 8.2/0.8 Hz, 1H), 7.18 (ddd, J = 
8.2/7.0/1.1 Hz, 1H), 7.04 (ddd, J = 7.9/7.2/0.9 Hz, 1H), 6.81 (d, J = 1.3 Hz, 1H), 3.96–3.48 (m, 8H); 
13C NMR (d6-DMSO) δ 162.1, 135.9, 129.6, 126.8, 123.2, 121.3, 119.7, 112.0, 104.1, 66.2, 47.9; m/z 
MS (TOF ES+) C13H15N2O2 [MH]
+ calcd 231.1; found 231.2; LCMS tR: 3.09 min (system B). 
N-Cyclopropyl-1H-indole-2-carboxamide (11o). Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to cyclopropylamine according to general procedure B. The crude precipitate was further 
purified by FCC (eluent EtOAc/PE 0:100 to 50:50) to give a white solid (contaminated with 6-chloro-
1H-benzo[d][1,2,3]triazol-1-ol). This was dissolved in EtOAc (30 mL) and washed with sat. 
NaHCO3(aq) (30 mL) and brine (30 mL), before concentrating to give 100 mg of white solid (81%). 
1H 
NMR (d6-DMSO) δ 11.52 (s, 1H), 8.44 (d, J = 3.9 Hz, 1H), 7.58 (dd, J = 7.9/0.5 Hz, 1H), 7.41 (dd, J = 
8.2/0.8 Hz, 1H), 7.16 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.08 (d, J = 1.4 Hz, 1H), 7.02 (ddd, J = 8.0/7.0/1.0 
Hz, 1H), 2.85 (ddddd, J = 7.9/7.9/7.9/4.0/4.0 Hz, 1H), 0.80 – 0.49 (m, 4H); 13C NMR (d6-DMSO) δ 
162.2, 136.4, 131.7, 127.1, 123.2, 121.4, 119.6, 112.3, 102.4, 22.6, 5.8; m/z MS (TOF ES+) C12H13N2O 
[MH]+ calcd 201.1; found 201.2; LCMS tR: 3.14 min (system B). 
N-Cyclobutyl-1H-indole-2-carboxamide (11p). Indole-2-carboxylic acid (100 mg, 0.62 mmol) was 
coupled to cyclobutylamine according to general procedure B. The crude precipitate was dissolved in 
EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and further purifying 
the residue by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 52 mg of white solid (39%). 1H NMR 
(d6-DMSO) δ 11.51 (s, 1H), 8.59 (d, J = 7.8 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.41 (dd, J = 8.2/0.8 Hz, 
1H), 7.25–7.08 (m, 2H), 7.02 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 4.57–4.33 (m, 1H), 2.31–2.17 (m, 2H), 
2.16–2.01 (m, 2H), 1.77–1.61 (m, 2H); 13C NMR (d6-DMSO) δ 160.0, 136.4, 131.7, 127.1, 123.2, 
121.4, 119.6, 112.3, 102.5, 44.1, 30.2, 14.7; m/z MS (TOF ES+) C13H15N2O [MH]
+ calcd 215.1; found 
215.2; LCMS tR: 6.00 min (system A). 
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 N-Cyclopentyl-1H-indole-2-carboxamide (11q).
32
 Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to cyclopentylamine according to general procedure B. The crude precipitate was 
dissolved in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and 
further purifying the residue by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 103 mg of off-white 
solid (73%). 1H NMR (d6-DMSO) δ 11.49 (s, 1H), 8.25 (d, J = 7.4 Hz, 1H), 7.59 (dd, J = 7.9/0.5 Hz, 
1H), 7.41 (dd, J = 8.2/0.8 Hz, 1H), 7.21–7.10 (m, 2H), 7.02 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 4.35–4.12 
(m, 1H), 1.98–1.80 (m, 2H), 1.80–1.38 (m, 6H); 13C NMR (d6-DMSO) δ 160.6, 136.3, 132.0, 127.1, 
123.1, 121.4, 119.6, 112.2, 102.5, 50.6, 32.2, 23.6; m/z MS (TOF ES+) C14H17N2O [MH]
+ calcd 229.1; 
found 229.1; LCMS tR: 3.34 min (system B). 
N-Cyclohexyl-1H-indole-2-carboxamide (11r).
31
 Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to cyclohexylamine according to general procedure B. The crude precipitate was dissolved 
in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and further 
purifying the residue by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 116 mg of off-white solid 
(77%). 1H NMR (d6-DMSO) δ 11.50 (s, 1H), 8.17 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.42 
(dd, J = 8.2/0.7 Hz, 1H), 7.22–7.10 (m, 2H), 7.02 (ddd, J = 7.9/ 7.1/0.9 Hz, 1H), 3.94–3.53 (m, 1H), 
1.97–1.52 (m, 5H), 1.46–0.98 (m, 5H); 13C NMR (d6-DMSO) δ 160.1, 136.3, 132.0, 127.1, 123.1, 
121.4, 119.6, 112.2, 102.5, 47.9, 32.6, 25.3, 24.9; m/z MS (TOF ES+) C15H19N2O [MH]
+ calcd 243.2; 
found 243.2; LCMS tR: 6.36 min (system A). 
N-(Piperidin-1-yl)-1H-indole-2-carboxamide (11s). Indole-2-carboxylic acid (100 mg, 0.62 mmol) 
was coupled to 1-aminopiperidne according to general procedure B. The crude precipitate was 
dissolved in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and 
further purifying the residue by FCC (eluent EtOAc/PE 10:90 to 100:0), to give 91 mg of off-white 
solid (60%). 1H NMR (d6-DMSO) δ 11.53 (s, 1H), 9.37 (s, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 
8.2 Hz, 1H), 7.16 (dd, J = 7.6/7.6 Hz, 1H), 7.09 (d, J = 1.1 Hz, 1H), 7.06–6.97 (m, 1H), 3.19–2.71 (m, 
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 4H), 1.87–1.26 (m, 6H); 13C NMR (d6-DMSO) δ 158.9, 136.3, 130.9, 127.0, 123.2, 121.4, 119.7, 
112.2, 102.3, 55.4, 40.2, 39.9, 39.7, 39.5, 39.3, 39.1, 38.9, 25.4, 23.1; m/z MS (TOF ES+) C14H18N3O 
[MH]+ calcd 244.1; found 244.2; LCMS tR: 3.13 min (system B). 
N-Phenyl-1H-indole-2-carboxamide (11t).
39
 Indole-2-carboxylic acid (100 mg, 0.62 mmol), HCTU 
(282 mg, 0.68 mmol, 1.1 eq) and aniline (0.068 mL, 0.74 mmol, 1.2 eq) were dissolved in DMF (1 mL) 
at rt, before adding DIPEA (0.129 mL, 0.74 mmol, 1.2 eq). The mixture was stirred at rt overnight, 
before adding water (10 mL), and allowed to stir for 10 min. The resulting precipitate was collected by 
filtration (vacuum), then redissolved in EtOAc (30 mL). This solution was then washed with sat. 
NaHCO3 (aq) (30 mL), before concentrating and further purifying the residue by FCC (eluent EtOAc/PE 
0:100 to 50:50), to give 118 mg of yellow solid (81%). 1H NMR (d6-DMSO) δ 11.74 (s, 1H), 10.20 (s, 
1H), 7.81 (dd, J = 8.6/1.0 Hz, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.52–7.41 (m, 2H), 7.38 (dd, J = 10.8/5.1 
Hz, 2H), 7.22 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.16–7.01 (m, 2H); 13C NMR (d6-DMSO) δ 159.7, 139.0, 
136.8, 131.5, 128.7, 127.0, 123.8, 123.5, 121.7, 120.1, 119.9, 112.4, 103.9; m/z MS (TOF ES+) 
C15H13N2O [MH]
+ calcd 237.1; found 237.1; LCMS tR: 3.37 min (system B). 
N-(Cyclopropylmethyl)-1H-indole-2-carboxamide (11u). Indole-2-carboxylic acid (100 mg, 0.62 
mmol) was coupled to cyclopropylmethylamine according to general procedure B. The mixture was 
diluted with water/sat. NaHCO3 (aq) (1:1), and the resulting precipitate collected by filtration (vacuum), 
and washed with water. After drying, 73 mg of white solid was obtained, requiring no further 
purification. 1H NMR (d6-DMSO) δ 11.54 (s, 1H), 8.54 (t, J = 5.7 Hz, 1H), 7.60 (d, J = 7.9 Hz, 1H), 
7.42 (dd, J = 8.2/0.8 Hz, 1H), 7.16 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.13–7.07 (m, 1H), 7.02 (ddd, J = 
8.0/7.0/1.0 Hz, 1H), 3.17 (dd, J = 6.3/6.3 Hz, 2H), 1.15–0.94 (m, 1H), 0.55–0.35 (m, 2H), 0.34–0.15 
(m, 2H); 13C NMR (d6-DMSO) δ 161.0, 136.3, 131.9, 127.1, 123.1, 121.4, 119.6, 112.2, 102.3, 43.1, 
11.1, 3.3; m/z MS (TOF ES+) C13H15N2O [MH]
+ calcd 215.1; found 215.1; LCMS tR: 3.24 min (system 
B). 
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 N-(Cyclohexylmethyl)-1H-indole-2-carboxamide (11v). Indole-2-carboxylic acid (100 mg, 0.62 
mmol) was coupled to cyclohexylmethylamine according to general procedure B. The crude precipitate 
was dissolved in EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and 
further purifying the residue by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 102 mg of white solid 
(64%). 1H NMR (d6-DMSO) δ 11.50 (s, 1H), 8.40 (t, J = 5.8 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.41 
(dd, J = 8.2/0.8 Hz, 1H), 7.16 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.12 (dd, J = 2.0/0.6 Hz, 1H), 7.02 (ddd, J 
= 8.0/7.1/0.9 Hz, 1H), 3.13 (dd, J = 6.4/6.4 Hz, 2H), 1.83–1.43 (m, 6H), 1.36–1.05 (m, 3H), 1.03–0.82 
(m, 2H); 13C NMR (d6-DMSO) δ 161.1, 136.3, 131.9, 127.1, 123.1, 121.4, 119.6, 112.2, 102.2, 45.0, 
37.6, 30.5, 26.1, 25.4; m/z MS (TOF ES+) C16H21N2O [MH]
+ calcd 257.2; found 257.2; LCMS tR: 3.50 
min (system B). 
N-Benzyl-1H-indole-2-carboxamide (11w).
31,32
 Indole-2-carboxylic acid (100 mg, 0.62 mmol) was 
coupled to benzylamine according to general procedure B. The crude precipitate was dissolved in 
EtOAc (30 mL) and washed with sat. NaHCO3 (aq) (30 mL), before concentrating and further purifying 
the residue by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 116 mg of white solid (74%). 1H NMR 
(d6-DMSO) δ 11.59 (s, 1H), 9.02 (t, J = 6.1 Hz, 1H), 7.61 (d, J = 7.9 Hz, 1H), 7.46–7.39 (m, 1H), 7.39–
7.30 (m, J = 4.4 Hz, 4H), 7.29–7.21 (m, 1H), 7.21–7.13 (m, 2H), 7.03 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 
4.52 (d, J = 6.1 Hz, 2H); 13C NMR (d6-DMSO) δ 161.1, 139.6, 136.5, 131.6, 128.3, 127.2, 127.1, 
126.8, 123.3, 121.5, 119.7, 112.3, 102.6, 42.1; m/z MS (TOF ES+) C16H15N2O [MH]
+ calcd 251.1; 
found 251.1; LCMS tR: 3.34 min (system B). 
3-Fluoro-N-isopropyl-1H-indole-2-carboxamide (13a). N-Isopropyl-1H-indole-2-carboxamide (3) 
(113 mg, 0.56 mmol) as dissolved in MeCN (5 mL), before adding sat. NaHCO3 (aq) (1 mL), and 
cooling to 0 °C. Once cooled, 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate) (Selectfluor®) (238 mg, 0.67 mmol, 1.2 eq) was added gradually, and the mixture 
stirred at rt for 5 h. TLC analysis (EtOAc/PE 3:7) indicated reaction progression had stopped, so the 
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 mixture was quenched with water (30 mL), before extracting with EtOAc (3 × 20 mL), and the 
combined organic extracts washed with brine (30 mL). After concentration, the crude residue was 
purified by FCC (eluent EtOAc/PE 0:100 to 30:70) to give 56 mg of off-white solid (46%). 1H NMR 
(d6-DMSO) δ 11.37 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.53 (d, J = 6.3 Hz, 1H), 7.39 (ddd, J = 
8.4/1.5/0.9 Hz, 1H), 7.25 (ddd, J = 8.3/7.0/1.1 Hz, 1H), 7.10 (ddd, J = 7.9/7.0/0.9 Hz, 1H), 4.31–3.96 
(m, 1H), 1.21 (d, J = 6.6 Hz, 6H); 19F NMR (376 MHz, d6-DMSO) δ -164.67; 
13C NMR (d6-DMSO) δ 
158.5 (d, JCF = 3.5 Hz), 142.7 (d, JCF = 250.4 Hz), 131.8 (d, JCF = 6.5 Hz), 124.6, 120.1, 117.2 (d, JCF = 
2.6 Hz), 115.2 (d, JCF = 15.8 Hz), 114.9 (d, JCF = 18.7 Hz), 112.7, 40.9, 22.2; m/z MS (TOF ES
+) 
C12H14FN2O [MH]
+ calcd 221.1; found 221.2; LCMS tR: 3.38 min (system B). 
4-Fluoro-N-isopropyl-1H-indole-2-carboxamide (13b). 4-Fluoroindole-2-carboxylic acid (12b) 
(100 mg, 0.56 mmol) and isopropylamine (0.142 mL, 1.67 mmol, 3 eq), were coupled according to 
general procedure B. Sat. NaHCO3 (aq) (1 mL) was added, followed by water. The resulting precipitate 
was collected by vacuum filtration, then washed with water, dried and further purified by FCC (eluent 
EtOAc/PE 0:100 to 40:60) to give 18 mg of yellow solid (15%). 1H NMR (d6-DMSO) δ 11.86 (s, 1H), 
8.30 (d, J = 7.8 Hz, 1H), 7.30–7.20 (m, 2H), 7.14 (td, J = 8.0, 5.4 Hz, 1H), 6.80 (ddd, J = 10.8/7.8/0.5 
Hz, 1H), 4.22–4.06 (m, 1H), 1.19 (d, J = 6.6 Hz, 6H); 19F NMR (376 MHz, d6-DMSO) δ -121.88; 
13C 
NMR (d6-DMSO) δ 159.7, 156.1 (d, JCF = 245.7 Hz), 138.8 (d, JCF = 10.8 Hz), 132.4, 123.6 (d, JCF = 
7.8 Hz), 116.2 (d, JCF = 22.0 Hz), 108.8 (d, JCF = 3.5 Hz), 103.9 (d, JCF = 18.4 Hz), 97.9, 40.7, 22.4; 
m/z MS (TOF ES+) C12H14FN2O [MH]
+ calcd 221.1; found 221.1; LCMS tR: 3.26 min (system B). 
5-Fluoro-N-isopropyl-1H-indole-2-carboxamide (13c). 5-Fluoroindole-2-carboxylic acid (12c) 
(100 mg, 0.56 mmol) and isopropylamine (0.142 mL, 1.67 mmol, 3 eq), were coupled according the 
general procedure B. The crude was purified by FCC (eluent EtOAc/PE 0:100 to 50:50) to give 90 mg 
of white solid (73%). 1H NMR (d6-DMSO) δ 11.61 (s, 1H), 8.25 (d, J = 7.8 Hz, 1H), 7.46–7.32 (m, 
2H), 7.13 (d, J = 1.5 Hz, 1H), 7.02 (ddd, J = 9.3/9.3/2.6 Hz, 1H), 4.28–3.96 (m, 1H), 1.18 (d, J = 6.6 
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 Hz, 1H); 19F NMR (376 MHz, d6-DMSO) δ -124.2; 
13C NMR (d6-DMSO) δ 159.9, 157.1 (d, JCF = 
232.3 Hz), 133.8, 133.0, 127.1 (d, JCF = 10.5 Hz), 113.4 (d, JCF = 9.8 Hz), 111.7 (d, JCF = 26.5 Hz), 
105.6 (d, JCF = 23.0 Hz), 102.4 (d, JCF = 5.1 Hz), 40.7, 22.4; m/z MS (TOF ES
+) C12H14FN2O [MH]
+ 
calcd 221.1; found 221.1; LCMS tR: 3.25 min (system B). 
6-Fluoro-N-isopropyl-1H-indole-2-carboxamide (13d). 6-Fluoroindole-2-carboxylic acid (12d) 
(100 mg, 0.56 mmol) isopropylamine (0.142 mL, 1.67 mmol, 3 eq), were coupled according to general 
procedure B. The crude was purified by FCC (eluent EtOAc/PE 0:100 to 50:50) to give 30 mg of pink 
solid (24%). 1H NMR (d6-DMSO) δ 11.58 (s, 1H), 8.21 (d, J = 7.8 Hz, 1H), 7.62 (dd, J = 8.7/5.5 Hz, 
1H), 7.15 (dd, J = 2.2/0.8 Hz, 1H), 7.13 (dd, J = 10.1/2.4 Hz, 1H), 6.89 (ddd, J = 9.8/8.8/2.4 Hz, 1H), 
4.27–3.98 (m, 1H), 1.18 (d, J = 6.6 Hz, 7H); 19F NMR (376 MHz, d6-DMSO) δ -119.0; 
13C NMR (d6-
DMSO) δ 159.9, 159.8 (d, JCF = 236.7 Hz), 136.2 (d, JCF = 12.9 Hz), 132.8 (d, JCF = 3.7 Hz), 123.9, 
122.8 (d, JCF = 10.4 Hz), 108.6 (d, JCF = 24.8 Hz), 102.5, 97.7 (d, JCF = 25.5 Hz), 40.7, 22.4; m/z MS 
(TOF ES+) C12H14FN2O [MH]
+ calcd 221.1; found 221.1; LCMS tR: 3.25 min (system B). 
7-Fluoro-N-isopropyl-1H-indole-2-carboxamide (13e). 7-Fluoroindole-2-carboxylic acid (12e) 
(100 mg, 0.56 mmol) and isopropylamine (0.142 mL, 1.67 mmol, 3 eq) were coupled according to 
general procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at 
rt for a further 5 min, causing precipitate formation. This was collected by filtration (vacuum), then 
washed with water, dried and further purified by FCC (eluent EtOAc/PE 0:100 to 50:50) to give 8 mg 
of white solid (7%). 1H NMR (d6-DMSO) δ 11.93 (s, 1H), 8.23 (d, J = 7.7 Hz, 1H), 7.51–7.36 (m, 1H), 
7.19 (dd, J = 3.2/2.1 Hz, 1H), 7.09–6.91 (m, 2H), 4.26–3.95 (m, 1H), 1.19 (d, J = 6.6 Hz, 6H); 19F 
NMR (376 MHz, d6-DMSO) δ -131.50; 
13C NMR (d6-DMSO) δ 159.5, 149.3 (d, JCF = 245.1 Hz), 
133.5, 130.8 (d, JCF = 5.7 Hz), 124.6 (d, JCF = 13.3 Hz), 119.9 (d, JCF = 6.0 Hz), 117.5 (d, JCF = 3.6 
Hz), 107.8 (d, JCF = 15.9 Hz), 104.1 (d, JCF = 2.1 Hz), 40.8, 22.4; m/z MS (TOF ES
+) C12H14FN2O 
[MH]+ calcd 221.1; found 221.1; LCMS tR: 3.25 min (system B). 
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 5-Methoxy-N-isopropyl-1H-indole-2-carboxamide (15). 5-Methoxyindole-2-carboxylic acid (14) 
(191 mg, 1.00 mmol) and isopropylamine (0.255 mL, 3.00 mmol, 3 eq) were coupled according to 
general procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at 
rt for a further 5 min, causing precipitate formation. This was collected by filtration (vacuum), then 
washed with water, dried and further purified by FCC (eluent EtOAc/PE 0:100 to 50:50) to give 185 
mg of off-white solid (80%). 1H NMR (d6-DMSO) δ 11.34 (s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 7.30 (d, J 
= 8.9 Hz, 1H), 7.05 (d, J = 2.4 Hz, 1H), 7.03 (dd, J = 2.1/0.7 Hz, 1H), 6.81 (dd, J = 8.9/2.5 Hz, 1H), 
4.18–4.05 (m, 1H), 3.75 (s, 3H), 1.18 (d, J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 160.2, 153.7, 132.4, 
131.6, 127.4, 114.2, 113.0, 102.1, 102.0, 55.3, 40.6, 22.5; m/z MS (TOF ES+) C13H17N2O2 [MH]
+ calcd 
233.3; found 233.2; LCMS tR: 3.53 min (system B). 
N-Isopropyl-1-methyl-1H-indole-2-carboxamide (17).
40
 1-Methyl-1H-indole-2-carboxylic acid 
(16) (175 mg, 1.00 mmol) and isopropylamine (0.255 mL, 3.00 mmol, 3 eq) were coupled according to 
general procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at 
rt for a further 5 min, causing precipitate formation. This was collected by filtration (vacuum), then 
washed with water, dried and further purified by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 195 
mg of yellow solid (90%). 1H NMR (d6-DMSO) δ 8.26 (d, J = 7.9 Hz, 1H), 7.66–7.56 (m, 1H), 7.51 
(dd, J = 8.4/0.7 Hz, 1H), 7.26 (ddd, J = 8.3/7.0/1.2 Hz, 1H), 7.14–6.99 (m, 2H), 4.17–4.03 (m, 1H), 
3.97 (s, 3H), 1.18 (d, J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 161.0, 138.3, 132.5, 125.6, 123.3, 121.4, 
120.0, 110.4, 104.1, 40.6, 31.3, 22.3; m/z MS (TOF ES+) C13H17N2O [MH]
+ calcd 217.1; found 217.2; 
LCMS tR: 3.73 min (system B). 
N-Isopropyl-1H-benzo[d]imidazole-2-carboxamide (19).
41
 1H-Benzo[d]imidazole-2-carboxylic 
acid (18) (162 mg, 1.00 mmol) and isopropylamine (0.255 mL, 3.00 mmol, 3 eq) were coupled 
according to general procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) 
and stirred at rt for a further 5 min, causing precipitate formation. This was collected by filtration 
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 (vacuum), then washed with water, dried and further purified by FCC (eluent EtOAc/PE 0:100 to 
50:50) to give 45 mg of off-white solid (22%). 1H NMR (d6-DMSO) δ 13.19 (s, 1H), 8.68 (d, J = 8.4 
Hz, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.58–7.45 (m, 1H), 7.33–7.28 (m, 1H), 7.28–7.22 (m, 1H), 4.32–4.08 
(m, 1H), 1.21 (d, J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 157.8, 145.9, 142.5, 134.4, 124.0, 122.5, 
119.8, 112.5, 40.8, 22.1; m/z MS (TOF ES+) C11H14N3O [MH]
+ calcd 204.1; found 204.2; LCMS tR: 
3.42 min (system B). 
N-Isopropylbenzo[d]oxazole-2-carboxamide (21).
42
 Potassium benzo[d]oxazole-2-carboxylate (20) 
(141 mg, 0.70 mmol) and isopropylamine (0.178 mL, 2.09 mmol, 3 eq) were coupled according to 
general procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at 
rt for a further 5 min, before extraction with EtOAc (3 × 20 mL). The combined organic layers were 
washed with brine (20 mL), before concentration under reduced pressure, and further purified by FCC 
(eluent EtOAc/PE 0:100 to 50:50) to give 42 mg of off-white solid (30%). 1H NMR (d6-DMSO) δ 9.11 
(d, J = 8.2 Hz, 1H), 7.92–7.81 (m, 2H), 7.60–7.53 (m, 1H), 7.53–7.46 (m, 1H), 4.23–4.01 (m, 1H), 1.20 
(d, J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 155.9, 154.2, 150.1, 139.8, 127.3, 125.6, 120.9, 111.8, 
41.3, 21.9; m/z MS (TOF ES+) C11H13N2O2 [MH]
+ calcd 205.2; found 205.1; LCMS tR: 3.54 min 
(system B). 
N-Isopropylbenzofuran-2-carboxamide (23a).
43
 Benzofuran-2-carboxylic acid (22a) (162 mg, 1.00 
mmol) and isopropylamine (0.255 mL, 3.00 mmol, 3 eq) were coupled according to general procedure 
B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at rt for a further 5 
min, causing precipitate formation. This was collected by filtration (vacuum), then washed with water, 
to give 160 mg of white solid (79%). 1H NMR (CDCl3) δ 7.67 (ddd, J = 7.8/1.2/0.7 Hz, 1H), 7.50 (dd, 
J = 8.3/0.8 Hz, 1H), 7.45 (d, J = 0.9 Hz, 1H), 7.41 (ddd, J = 8.4/7.2/1.3 Hz, 1H), 7.29 (ddd, J = 
8.1/7.3/1.0 Hz, 1H), 6.46 (d, J = 5.7 Hz, 1H), 4.49–4.17 (m, 1H), 1.31 (d, J = 6.6 Hz, 6H); 13C NMR 
Page 58 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 (CDCl3) δ 158.2, 154.8, 149.1, 127.9, 126.9, 123.8, 122.9, 111.8, 110.3, 41.6, 23.0; m/z MS (TOF ES
+) 
C12H14NO2 [MH]
+ calcd 204.1; found 204.2; LCMS tR: 3.62 min (system B). 
N-Isopropylbenzofuran-3-carboxamide (23b). Benzofuran-3-carboxylic acid (22b) (162 mg, 1.00 
mmol) and isopropylamine (0.255 mL, 3.00 mmol, 3 eq) were coupled according to general procedure 
B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at rt for a further 5 
min, causing precipitate formation. This was collected by filtration (vacuum), then washed with water, 
dried and further purified by FCC (eluent EtOAc/PE 0:100 to 50:50), to give 117 mg of yellow solid 
(58%). 1H NMR (d6-DMSO) δ 8.54 (s, 1H), 8.10 (d, J = 7.5 Hz, 1H), 8.08–8.01 (m, 1H), 7.68–7.58 (m, 
1H), 7.42–7.28 (m, 2H), 4.32–3.86 (m, 1H), 1.18 (d, J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 161.2, 
154.6, 147.0, 125.4, 125.0, 123.6, 122.0, 117.1, 111.5, 40.5, 22.4; m/z MS (TOF ES+) C12H14NO2 
[MH]+ calcd 204.1; found 204.2; LCMS tR: 3.61 min (system B). 
N-Isopropylbenzo[b]thiophene-2-carboxamide (25a).
44
 Benzo[b]thiophene-2-carboxylic acid 
(24a) (178 mg, 1.00 mmol) and isopropylamine (0.255 mL, 3.00 mmol, 3 eq) were coupled according 
to general procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred 
at rt for a further 5 min, causing precipitate formation. This was collected by filtration (vacuum), then 
washed with water, to give 164 mg of white solid (75%). 1H NMR (CDCl3) δ 7.92–7.78 (m, 2H), 7.74 
(s, 1H), 7.47–7.34 (m, 2H), 5.89 (d, J = 5.5 Hz, 1H), 4.42–4.18 (m, 1H), 1.29 (d, J = 6.6 Hz, 6H); 13C 
NMR (CDCl3) δ 161.6, 148.7, 140.9, 139.3, 126.4, 125.1, 125.1, 125.0, 122.9, 42.4, 23.0; m/z MS 
(TOF ES+) C12H14NOS [MH]
+ calcd 220.1; found 220.1; LCMS tR: 3.70 min (system B). 
N-Isopropylbenzo[b]thiophene-3-carboxamide (25b). Benzo[b]thiophene-3-carboxylic acid (24b) 
(178 mg, 1.00 mmol) and isopropylamine (0.255 mL, 3.00 mmol, 3 eq) were coupled according to 
general procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at 
rt for a further 5 min, causing precipitate formation. This was collected by filtration (vacuum), then 
washed with water, to give 195 mg of white solid (89%). 1H NMR (CDCl3) δ 8.34 (d, J = 7.8 Hz, 1H), 
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 7.86 (ddd, J = 7.9/1.2/0.7 Hz, 1H), 7.82 (s, 1H), 7.46 (ddd, J = 8.2/7.1/1.3 Hz, 1H), 7.43–7.37 (m, 1H), 
5.84 (s, 1H), 4.53–4.15 (m, 1H), 1.30 (d, J = 6.6 Hz, 6H); 13C NMR (CDCl3) δ 166.8, 143.2, 140.4, 
136.9, 128.8, 125.2, 124.3, 122.7, 118.7, 41.9, 23.1; m/z MS (TOF ES+) C12H14NOS [MH]
+ calcd 
220.1; found 220.1; LCMS tR: 3.68 min (system B). 
N-Isopropyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (27). 1H-Pyrrolo[2,3-b]pyridine-2-
carboxylic acid (26) (103 mg, 0.64 mmol) and isopropylamine (0.164 mL, 1.92 mmol, 3 eq) were 
coupled together according to general procedure B. After an overnight period of stirring, the carboxylic 
acid starting material had disappeared, however, the isouronium intermediate was still present, and 
appeared to be only partially soluble in the reaction mixture. DCM (1 mL) and further isopropylamine 
(0.273 mL, 3.2 mmol, 5 eq) was added and stirring continued for a further overnight period. The 
mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at rt for a further 5 min, 
causing precipitate formation. This was collected by filtration (vacuum), then washed with water, to 
give 86 mg of white solid (66%). 1H NMR (d6-DMSO) δ 12.03 (s, 1H), 8.32 (dd, J = 4.6/1.5 Hz, 1H), 
8.24 (d, J = 7.6 Hz, 1H), 8.05 (dd, J = 7.9/1.4 Hz, 1H), 7.20–7.02 (m, 2H), 4.42–3.72 (m, 1H), 1.19 (d, 
J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 159.6, 148.3, 145.1, 132.5, 129.9, 119.3, 116.3, 101.7, 40.8, 
22.4; m/z MS (TOF ES+) C11H14N3O [MH]
+ calcd 204.1; found 204.2; LCMS tR: 4.98 min (system A). 
1H-Indole-4-carboxylic acid (29a). Methyl 1H-indole-4-carboxylate (28a) underwent hydrolysis 
according to general procedure C, to give 72 mg (78%) of pale orange solid. 
1H NMR (d6-DMSO) δ 11.38 (s, 1H), 7.71 (dd, J = 7.4/1.0 Hz, 1H), 7.65 (ddd, J = 8.0/0.9/0.9 Hz, 
1H), 7.49 (dd, J = 2.8/2.8 Hz, 1H), 7.22–7.08 (m, 1H), 6.95 (ddd, J = 3.0/2.0/0.9 Hz, 1H); 13C NMR 
(d6-DMSO) δ 168.5, 136.7, 127.3, 127.2, 122.3, 121.4, 120.1, 116.2, 102.3; m/z MS (TOF ES
-) 
C9H6NO2 [M-H]
- calcd 160.0; found 160.1; LCMS tR: 3.21 min (system B). 
1H-Indole-5-carboxylic acid (29b). Methyl 1H-indole-5-carboxylate (28b) underwent hydrolysis 
according to general procedure C, to give 95 mg (quantitative) of pale orange solid. 
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 1H NMR (d6-DMSO) δ 11.42 (s, 1H), 8.23 (s, 1H), 7.70 (dd, J = 8.5/1.6 Hz, 1H), 7.52–7.35 (m, 2H), 
6.65–6.49 (m, 1H); 13C NMR (d6-DMSO) δ 168.4, 138.3, 127.2, 126.9, 122.8, 122.2, 121.4, 111.1, 
102.47; m/z MS (TOF ES-) C9H6NO2 [M-H]
- calcd 160.0; found 160.1; LCMS tR: 3.23 min (system B). 
1H-Indole-6-carboxylic acid (29c). Methyl 1H-indole-6-carboxylate (28c) underwent hydrolysis 
according to general procedure C, to give 94 mg (quantitative) of pale orange solid. 1H NMR (d6-
DMSO) δ 11.44 (s, 1H), 8.04 (ddd, J = 1.0/1.0/1.0 Hz, 1H), 7.62–7.58 (m, 2H), 7.58–7.54 (m, 1H), 
6.51 (ddd, J = 2.9/1.9/0.9 Hz, 1H); 13C NMR (d6-DMSO) δ 168.4, 135.2, 131.0, 128.9, 123.1, 119.8, 
119.6, 113.5, 101.4; m/z MS (TOF ES-) C9H6NO2 [M-H]
- calcd 160.0; found 160.1; LCMS tR: 3.35 min 
(system B). 
1H-Indole-7-carboxylic acid (29d). Methyl 1H-indole-7-carboxylate (28d) underwent hydrolysis 
according to general procedure C, to give 100 mg (quantitative) of orange solid. 1H NMR (d6-DMSO) δ 
11.05 (s, 1H), 7.83 (d, J = 7.8 Hz, 1H), 7.74 (dd, J = 7.5/1.0 Hz, 1H), 7.36 (dd, J = 2.8/2.8 Hz, 1H), 
7.10 (dd, J = 7.6/7.6 Hz, 1H), 6.54 (dd, J = 3.1/2.0 Hz, 1H); 13C NMR (d6-DMSO) δ 168.0, 134.6, 
129.3, 126.8, 125.6, 123.8, 118.4, 113.5, 101.5; m/z MS (TOF ES-) C9H6NO2 [M-H]
- calcd 160.0; 
found 160.1; LCMS tR: 3.48 min (system B). 
N-Isopropyl-1H-indole-4-carboxamide (30a). 1H-Indole-4-carboxylic acid (29a) (64 mg, 0.40 
mmol) and isopropylamine (0.102 mL, 1.20 mmol, 3 eq) were coupled together according to general 
procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at rt for 
30 min, causing precipitate formation. This was collected by filtration (vacuum), then washed with 
water, to give 32 mg (40%) of off-white solid, requiring no further purification. 1H NMR (d6-DMSO) δ 
11.24 (s, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.51 (ddd, J = 8.1/0.8/0.8 Hz, 1H), 7.46–7.38 (m, 1H), 7.37 (dd, 
J = 7.3/0.8 Hz, 1H), 7.16–7.04 (m, 1H), 6.80 (ddd, J = 2.9/2.0/0.8 Hz, 1H), 4.31–3.99 (m, 1H), 1.19 (d, 
J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 167.0, 136.5, 127.2, 126.2, 125.9, 120.1, 118.3, 113.8, 101.8, 
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 40.6, 22.4; m/z MS (TOF ES+) C12H15N2O [MH]
+ calcd 203.1; found 203.2; LCMS tR: 3.36 min 
(system B). 
N-Isopropyl-1H-indole-5-carboxamide (30b).
45
 1H-Indole-5-carboxylic acid (29b) (80 mg, 0.50 
mmol) and isopropylamine (0.128 mL, 1.50 mmol, 3 eq) were coupled together according to general 
procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at rt for 
30 min, before extraction with EtOAc (3 × 20 mL). The combined organic layers were washed with 
brine (20 mL), before concentration under reduced pressure, and further purification by FCC (eluent 
EtOAc/PE 0:100 to 100:0), to give 180 mg of clear colourless oil. This was diluted with DCM, and the 
resulting precipitate removed by filtration. After concentration of the filtrate, the resulting residue was 
triturated with water to give 66 mg (65%) of glassy solid. 1H NMR (d6-DMSO) δ 11.27 (s, 1H), 8.17–
8.07 (m, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.62 (dd, J = 8.5/1.7 Hz, 1H), 7.49–7.31 (m, 2H), 6.51 (ddd, J = 
2.9/1.9/0.8 Hz, 1H), 4.24–3.99 (m, 1H), 1.17 (d, J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 166.4, 137.3, 
126.9, 126.5, 125.9, 120.6, 119.8, 110.7, 102.0, 40.8, 22.5; m/z MS (TOF ES+) C12H15N2O [MH]
+ calcd 
203.1; found 203.1; LCMS tR: 3.37 min (system B). 
N-Isopropyl-1H-indole-6-carboxamide (30c). 1H-Indole-6-carboxylic acid (29c) (70 mg, 0.43 
mmol) and isopropylamine (0.111 mL, 1.29 mmol, 3 eq) were coupled together according to general 
procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at rt for 
30 min, before extraction with EtOAc (3 × 20 mL). The combined organic layers were washed with 
brine (20 mL), before concentration under reduced pressure, and further purification by FCC (eluent 
EtOAc/PE 0:100 to 100:0), to give 105 mg of clear colourless oil. This was triturated with water to give 
52 mg (60%) of glassy solid. 1H NMR (d6-DMSO) δ 11.32 (s, 1H), 8.09 (d, J = 7.2 Hz, 1H), 7.93 (s, 
1H), 7.76–7.16 (m, 3H), 6.47 (s, 1H), 4.41–3.80 (m, 1H), 1.17 (d, J = 6.5 Hz, 6H); 13C NMR (d6-
DMSO) δ 166.3, 135.2, 129.6, 127.8, 123.6, 119.2, 118.1, 111.2, 101.1, 40.8, 22.5; m/z MS (TOF ES+) 
C12H15N2O [MH]
+ calcd 203.1; found 203.1; LCMS tR: 3.41 min (system B). 
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 N-Isopropyl-1H-indole-7-carboxamide (30d). 1H-Indole-7-carboxylic acid (29d) (70 mg, 0.43 
mmol) and isopropylamine (0.111 mL, 1.29 mmol, 3 eq) were coupled together according to general 
procedure B. The mixture was quenched with sat. NaHCO3 (aq)/water (1:1, 10 mL) and stirred at rt for 
30 min, causing precipitate formation. This was collected by filtration (vacuum), then washed with 
water, to give 66 mg (76%) of orange solid, requiring no further purification. 1H NMR (d6-DMSO) δ 
11.11 (s, 1H), 8.26 (d, J = 7.7 Hz, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.66 (d, J = 7.5 Hz, 1H), 7.33 (dd, J = 
2.8/2.8 Hz, 1H), 7.05 (dd, J = 7.6/7.6 Hz, 1H), 6.47 (dd, J = 3.1/2.1 Hz, 1H), 4.34–4.04 (m, 1H), 1.21 
(d, J = 6.6 Hz, 6H); 13C NMR (d6-DMSO) δ 166.2, 134.2, 129.1, 126.5, 123.5, 119.8, 117.9, 117.2, 
100.9, 40.6, 22.4; m/z MS (TOF ES+) C12H15N2O [MH]
+ calcd 203.1; found 203.2; LCMS tR: 3.65 min 
(system B). 
tert-Butyl (4-hydroxybutyl)carbamate (32). 4-Aminopentanol (31) (196 mg, 2.20 mmol, 1.1 eq) 
was stirred in DCM (30 mL) at rt, before adding TEA (0.307 mL, 2.20 mmol, 1.1 eq) followed by 
dropwise addition of di-tert-butyl dicarbonate (437 mg, 2.00 mmol) solution in DCM (5 mL). After 24 
h, the mixture was washed with 1 M KHSO4 (aq) (2 × 20 mL), brine (20 mL), dried over Na2SO4 then 
concentrated under reduced pressure to give the title compound as a colourless oil (286 mg, 82%).1H 
NMR (CDCl3) δ 4.65 (s, 1H), 3.67 (t, J = 6.0 Hz, 2H), 3.16 (dd, J = 12.1/6.2 Hz, 2H), 1.78 (s, 1H), 
1.68–1.51 (m, 4H), 1.51–1.38 (m, 9H). 13C NMR (CDCl3) δ 156.3, 79.2, 62.6, 40.4, 29.9, 28.6, 26.8. 
4-((tert-Butoxycarbonyl)amino)butyl methanesulfonate (33). To a solution of tert-butyl (4-
hydroxybutyl)carbamate (32) (150 mg, 0.79 mmol) in DCM (20 mL) was added TEA (0.220 mL, 1.58 
mmol, 2 eq), followed by methanesulfonyl chloride (109 mg, 0.95 mmol, 1.2 eq). After 16 h stirring at 
rt, the solution was washed with 1 M NaOH (aq) (20 mL), 1 M KHSO4 (aq) (20 mL), brine (20 mL), then 
dried over Na2SO4 and concentrated under reduced pressure to afford the title compound as a yellow oil 
(196 mg, 93%). 1H NMR (CDCl3) δ 4.66 (br s, 1H), 4.25 (t, J = 6.4 Hz, 2H), 3.22–3.11 (m, 2H), 3.02 
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 (s, 3H), 1.84–1.74 (m, 2H), 1.68–1.52 (m, 2H), 1.43 (s, 9H). 13C NMR (CDCl3) δ 156.1, 79.3, 69.7, 
39.8, 37.4, 28.5, 26.5, 26.3. 
tert-Butyl (4-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)butyl)carbamate (34). To a solution of 4-
((tert-butoxycarbonyl)amino)butyl methanesulfonate (33) (202 mg, 0.76 mmol)  in DCM (15 mL) was 
added 7-cyano-1,2,3,4-tetrahydroisoquinoline (131 mg, 0.83 mmol, 1.1eq), followed by N,N-
diisopropylethylamine (156 µL, 0.91 mmol, 1.2eq). The solution was heated at reflux for 3 d, then 
concentrated under reduced pressure and the product purified by FCC (EtOAc) to give the title 
compound as a yellow oil (36 mg, 12%). 1H NMR (CDCl3) δ 7.40 (dd, J = 7.9/1.6 Hz, 1H), 7.32 (s, 
1H), 7.19 (d, J = 7.9 Hz, 1H), 4.99 (s, 1H), 3.62 (s, 2H), 3.15 (dd, J = 12.2/6.1 Hz, 2H), 2.96 (t, J = 5.8 
Hz, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.54 (t, J = 7.0 Hz, 2H), 1.71–1.50 (m, 4H), 1.42 (s, 9H). 13C NMR 
(CDCl3) δ 156.2, 140.4, 136.3, 130.5, 129.73, 129.65, 119.2, 109.5, 79.1, 57.8, 55.5, 50.3, 40.5, 29.5, 
28.5, 28.0, 24.5. 
N-(4-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-1H-indole-2-carboxamide (36).  
tert-Butyl (4-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)butyl)carbamate (34) (36 mg, 0.11 mmol) 
was taken up in DCM (5 mL) and TFA (1 mL) and stirred at rt for 16 h. After this, the mixture was 
diluted with DCM (20 mL) and water (5 mL) added. The pH of the aqueous layer was adjusted to ~10 
by dropwise addition of NH4OH (approximately 3 mL). Subsequently, the aqueous layer was extracted 
further with DCM (2 × 15 mL). The combined organic layers were washed with brine (20 mL), then 
dried over Na2SO4 and concentrated under reduced pressure to give the free amine intermediate 35. 
This was immediately taken up in DMF (5 mL) under a nitrogen atmosphere. 1H-Indole-2-carboxylic 
acid (21 mg, 0.13 mmol, 1.2 eq), HCTU (68 mg, 0.17 mmol, 1.5 eq) and DIPEA (0.096 mL, 0.55 
mmol, 5 eq) were added, and the mixture stirred at rt for 16 h. The mixture was concentrated under 
reduced pressure, before adding 2M NaHCO3 (aq), then extracting the resulting aqueous slurry with 
EtOAc (20 mL). The organic layer was washed with 2M NaHCO3 (aq) (2 × 20 mL), brine (20 mL), then 
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 dried over Na2SO4 before concentrating under reduced pressure. The resulting crude product was 
purified by FCC (eluent MeOH/CHCl3 5:95) to give 28 mg of white solid (69%). 
1H NMR (d6-DMSO) 
δ 8.44 (t, J = 5.7 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.57–7.53 (m, 2H), 7.41 (dq, J = 8.3/0.9 Hz, 1H), 
7.30 (d, J = 8.5 Hz, 1H), 7.16 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.08 (dd, J = 2.1/0.7 Hz, 1H), 7.02 (ddd, J 
= 8.0/7.0/1.0 Hz, 1H), 3.57 (s, 2H), 3.32–3.28 (m, 2H), 2.87 (t, J = 6.2 Hz, 2H), 2.66 (t, J = 5.8 Hz, 
2H), 2.49–2.46 (m, 2H), 1.59 (dt, J = 6.7/3.5 Hz, 4H). 13C NMR (d6-DMSO) δ 161.0, 140.7, 136.7, 
136.3, 131.9, 130.3, 129.7, 129.4, 127.1, 123.1, 121.4, 119.6, 119.1, 112.3, 108.2, 102.2, 57.0, 54.8, 
49.7, 38.7, 28.9, 27.1, 23.9. HRMS (m/z): [MH]+ calcd. for C23H24N4O, 373.2023; found 373.2022; 
HPLC tR = 7.2 min. 
 
Pharmacology. 
Materials: Dulbecco’s modified Eagle’s medium, Flp-In CHO cells, and hygromycin B were purchased 
from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from ThermoTrace 
(Melbourne, VIC, Australia). [3H]spiperone, [35S]GTPγS (1000 Ci/mmol), AlphaScreen reagents and 
Ultima gold scintillation cocktail were from PerkinElmer (Boston, MA). pcDNA3L-His-CAMYEL was 
purchased from ATCC. All other reagents were purchased from Sigma Aldrich (St. Louis, MO). The G 
protein BRET constructs were generated by Dr. Céline Galés (Paul Sabatier University, France).  
Cell culture and membrane preparation: was performed as described previously.46  
Molecular Biology: cDNA in pcDNA3.1+ encoding the long isoform of the wild-type human D2 
dopamine receptor (D2LR) was obtained from Missouri University of Science and Technology 
(http://www.cdna.org).  Oligonucleotides were purchased from GeneWorks (Hindmarsh, Australia). An 
N-terminal c-myc epitope tag (EQKLISEEDL) was introduced to the sequence of the D2LR and 
flanking AttB sites were introduced to the WT D2LR by overlap extension polymerase chain reaction to 
Page 65 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 allow sub-cloning into the pDONR201TM vector. The WT or c-myc tagged wildtype (WT) D2LR 
receptor construct in pDONR201™ were subsequently transferred into the pEF5/frt/V5/dest vector 
using the LR clonase enzyme mix (Invitrogen).  Desired mutations were introduced using the 
Quikchange™ site-directed mutagenesis kit (Agilent). Receptor constructs in pEF5/frt/V5/dest were 
used to transfect Flp-In CHO cells (Invitrogen). Cells were transfected using linear polyethyleneimine 
(PEI, Polysciences, Warrington, PA) as described previously.47 
ERK1/2 phosphorylation assay: Experiments were performed as described previously.46 Concentration-
response stimulation or inhibition curves were generated by exposure of the cells to antagonist ligand 
for 30 min and then dopamine for 5 min. Data were normalized to the response generated by 10% fetal 
bovine serum. 
BRET cAMP assay: D2LR-Flp-In CHO cells were transfected with 2µg of pcDNA3L-His-CAMYEL. 
The assay was performed as described previously13 with the following difference: 30 min prior to 
agonist addition appropriate concentrations of 1 or fragment ligand were added. 5 min following 
agonist addition 10 µL of forskolin was added to a final concentration of 3 µM. Data were normalized 
to the level of cAMP generated by 3 µM forskolin. 
[
35
S]GTPγS Binding Assay: Cell membranes (5 µg D2L-Flp-In CHO or 20 µg rat striatal tissue) were 
equilibrated for 60 min at 30 °C with varying concentrations of ligands in binding buffer (20 mM 
HEPES, 10 mM MgCl2, 100 mM NaCl 1 mM EGTA, 1 mM EDTA, 0.1% ascorbic acid, 1 mM DTT; 
pH 7.4) containing 3 µM GDP. [35S]GTPγS (0.1 nM) was added to a final volume of 0.2 mL (D2L-Flp-
In CHO) and membranes were incubated for further 60 min at 30 °C. 5 µg of saponin was added per 
assay point. For experiments using D2L-Flp-In CHO membranes termination of [
35S]GTPγS binding 
was by rapid filtration with a Packard plate harvester onto 96-well GF/C filter plates followed by three 
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 washes with ice cold 0.9% NaCl. Bound radioactivity was measured in a Microbeta microplate counter 
(Perkin Elmer). Data were normalized to the maximal response of dopamine in the control condition. 
[
3
H]spiperone binding assay: Experiments were performed using a methodology described 
previously46. 
β-arrestin recruitment: HEK293T cells were transfected with a 2:2:4 ratio of cDNA coding for D2L-
Rluc8, GRK2 and β-arrestin 2-YFP. Experiments were performed as described previously.48 
Antagonists were added 30 min prior to coelenterazine-h. Data were normalised to the maximal 
response of dopamine in the control condition. 
G Protein Activation: Flp-In-CHO cells stably expressing the D2LR were seeded at a density of 
2,000,000 cells per 10cm dish and were transfected the following day using polyethylenimine as 
transfection reagent. To measure the activation of Gαi1 and GαOB G proteins the cells were transfected 
with either 0.3 µg Rluc8-tagged Gαi1, 1.2 µg Gβ and 1.35 µg Venus-tagged Gγ; or 0.14 µg Rluc8-
tagged GαOB 1.2 µg Gβ and 0.6 µg Venus-tagged Gγ. 24 h after transfection the cells were plated into 
96-well CulturPlates (PerkinElmer) and grown overnight. The cells were equilibrated in Hank’s 
balanced salt solution at 37 °C before starting the experiment. The cells were stimulated with the 
agonists for the indicated timeframes when the BRET readings were captured. Coelenterazine 
(Promega) was added at a final concentration of 5 µM at least 3 min prior to measurement.  The signals 
were detected at 445-505 and 505-565 nm using a PHERAstar FS instrument (BMG LabTech, 
Offenburg, Germany). Net BRET was determined by subtraction of the vehicle control from the agonist 
induced response.   
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 Data analysis: GraphPad Prism 6.0b (San Diego, CA) was used for all statistical analysis, nonlinear 
regression, and simulations. 
Analysis of radioligand binding experiments:  
Competition-binding curves between [3H]spiperone and dopamine in the absence or presence of 3 were 
initially fitted to a one-site binding equation and two-site binding equation followed by F-test analysis 
for best fit.26 Subsequently, data of experiments using membranes of WT D2R FlpIn CHO cells was 
fitted to the following allosteric ternary complex model:49
   
 
 = 	
  + 	
     (1) 
Where Y is percentage (vehicle control) binding, [A], [B], and [I] are the concentrations of 
[3H]spiperone, 3, and dopamine, respectively, KA and KB are the equilibrium dissociation constants of 
[3H]spiperone and 1, respectively, KHi and KLo are the equilibrium dissociation constants of dopamine 
for the high- and low-affinity receptor state, respectively, FracHi is the proportion of receptors in the 
high-affinity receptor state, and α and α′ are the cooperativities between 1 and [3H]spiperone or 
dopamine, respectively. Values of α (or α ′) > 1 denote positive cooperativity; values < 1 (but > 0) 
denote negative cooperativity, and values = 1 denote neutral cooperativity.  
Competition-binding curves between [3H]spiperone and 1 or 3 could be fit to the allosteric ternary 
complex model using the following equation:50 
 =   
                                                   (2) 
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 Where Y is percentage (vehicle control) binding; [A] and [B] are the concentrations of [3H]spiperone 
and 1 or 3, respectively; KA and KB are the equilibrium dissociation constants of [
3H]spiperone and 1 or 
3, respectively; α is the cooperativity between 1 or 3 and [3H]spiperone. Values of α > 1 denote 
positive cooperativity; values < 1 (but  > 0) denote negative cooperativity, and values = 1 denote 
neutral cooperativity. 
Analysis of functional data: All concentration response (C/R) data were fitted to the following modified 
four-parameter Hill equation to derive potency estimates:26 
           (3)
 
Where E is the effect of the system, nH is the Hillslope, and EC50 is the concentration of agonist [A] 
that gives the midpoint response between basal and maximal effect of dopamine or other agonists 
(Emax), which are the lower and upper asymptotes of the response, respectively. 
Functional data describing the interaction between 2 and dopamine in [35S]GTPγS or cAMP assays 
were globally analyzed according to the allosteric ternary complex model. 
          
 
     
(4)
 
Where Em is the maximum possible cellular response, [A] and [B] are the concentrations of orthosteric 
and allosteric ligands, respectively, and KB is the equilibrium dissociation constant of the allosteric 
E =
Em .[A]
nH
[A]nH + [EC50]
nH
1+
[B]
KB
1+
αβ[B]
KB
 
 
 
 
  
 
 
 
 
  
E = Basal +
(Emax − Basal).[A]
nH
[A]nH + EC50
nH
Page 69 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 ligand, αβ is a composite cooperativity parameter between the orthosteric and allosteric ligand that 
includes effects upon orthosteric ligand affinity and efficacy and nH is the Hill slope of the orthosteric 
agonist concentration-response curve.  Values of α  and/or β greater than 1 denote allosteric 
potentiation, whereas values less than 1 (but greater than 0) denote allosteric inhibition. 
Functional data describing the interaction between 3, 11a or derivatives and dopamine at the D2R in a 
pERK1/2 assay were analyzed using a complete operational model of allosterism and agonism 
according to equation 5:51 
           (5)
 
Where Em is the maximum possible cellular response, [A] and [B] are the concentrations of orthosteric 
and allosteric ligands, respectively, KA and KB are the equilibrium dissociation constant of the 
orthosteric and allosteric ligands, respectively, and τB (constrained to -100) are operational measures of 
orthosteric and allosteric ligand efficacy (which incorporate both signal efficiency and receptor 
density), respectively, α is the binding cooperativity parameter between the orthosteric and allosteric 
ligand, and β (constrained to -100 to represent high negative cooperativity with dopamine efficacy) 
denotes the magnitude of the allosteric effect of the modulator on the efficacy of the orthosteric 
agonist. KA constrained to 11 nM, 188 nM and 191 nM for the WT, V91A and E95A receptors 
respectively and represents a value of functional affinity determined by an operational model of partial 
agonism to dose-response data of dopamine (a partial agonist) and apomorphine (a full agonist) in an 
pERK1/2 assay). LogτA was determined as 0.74 ± 0.07, 0.65 ± 0.19, 0.71 ± 0.24 at the WT, V91A and 
E95A D2R expressing cell lines respectively. For compounds that caused a limited rightward shift of 
the dopamine dose-response curve but no decrease in Emax data were fit using an operational model of 
E =
Em (τA [A](KB + αβ[B]) +τB [B]KA )
nH
([A]KB + KAKB + KA[B] + α[A][B])
nH + (τA [A](KB + αβ[B]) +τB [B]KA )
nH
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 allosterism where Logβ was constrained to 0 to represent neutral cooperativity with dopamine efficacy. 
For compounds that produced an unlimited rightward shift of a dopamine dose-response curve within 
the concentration range of test compound used data were fit using an operational model of allosterism 
where both Logα and Logβ were constrained to -100 and 0 respectively to allow estimation of 
compound affinity.  
A logistic equation of competitive agonist-antagonist interaction was globally fitted to data from 
functional experiments measuring the interaction between dopamine and test compounds which caused 
an unlimited rightward displacement of a dopamine dose-response curve and no decrease in Emax within 
the range of concentrations used26: 
!"#$%&#" = '%((%) + *+,-./00/1

2
34567894: 45;
<
 =
>
?                                                (6) 
Where s represents the Schild slope for the test compound and KB is the equilibrium dissociation 
constant of the test compound, nH is the Hillslope, and EC50 is the concentration of agonist [A] that 
gives the midpoint response between basal and maximal effect of dopamine or other agonists (Emax), 
which are the lower and upper asymptotes of the response, respectively. 
 
Statistical Analysis: All data points and values shown in the figures and tables are the means ± SEM of 
at least 3 separate experiments performed in duplicate unless otherwise stated. Statistically significant 
differences (taken at p < 0.05) between pKB, Logα   or Logβ  values were determined by one-way 
ANOVA with a Bonferroni post-test or an unpaired Student’s t-test as appropriate. 
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 Supporting Information. Supplementary Table 1: Allosteric ternary complex model binding 
parameters for the interaction between 3, dopamine and [3H]spiperone at the D2LR expressed in Flp-In 
CHO cells. 
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